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8ABSTRACT
Clopidogrel, an adenosine diphosphate receptor subtype P2Y12 antagonist, attenuates platelet
activation via its active cis-thiol metabolite formed in two steps predominantly by cytochrome P450
(CYP) 2C19 and CYP3A4. It is widely used in acute treatment and secondary prevention of
atherothrombotic events. A previous clinical study observed clopidogrel to markedly increase the
exposure of CYP2C8 index substrate repaglinide, whose disposition is additionally dictated by CYP3A4
and the hepatic uptake transporter organic anion-transporting polypeptide (OATP) 1B1. In vitro
experiments identified the secondary acyl-?-D-glucuronide metabolite of clopidogrel as a time-
dependent inhibitor of CYP2C8, but they also suggested clopidogrel to inhibit OATP1B1 and CYP3A4.
The primary aim of this work was to characterize the drug-drug interaction (DDI) mechanisms of
clopidogrel and their clinically relevant implications, while the secondary objective was to search for
sensitive and selective CYP2C8 index substrates. This thesis consists of five prospective, clinical
pharmacokinetic and pharmacodynamic DDI studies applying randomized, controlled, crossover design.
In the first study, clopidogrel did not affect the pharmacokinetics of simvastatin, leading to the
conclusion that clopidogrel is not a clinically relevant inhibitor of OATP1B1 or CYP3A4, which have
paramount roles in the disposition of simvastatin. The second study reported clopidogrel to augment
the exposure and trough concentration of the CYP2C8 substrate pioglitazone 2.1-fold and 4.5-fold,
respectively. These observations implied that coadministering the two drugs might increase the risk for
adverse reactions caused by pioglitazone due to the inhibition of its CYP2C8-mediated metabolism by
clopidogrel. In the third study, clopidogrel doubled the exposure montelukast, whereas prasugrel did
not significantly affect montelukast pharmacokinetics. These findings indicate that montelukast is less
sensitive to CYP2C8 inhibition than suggested by previous studies with the strong CYP2C8 inhibitor
gemfibrozil, and confirm that clopidogrel, but not prasugrel, is a potent inhibitor of CYP2C8. The fourth
study found clopidogrel to increase the exposure of the CYP2C8 substrate dasabuvir ~4–5-fold and
observed ritonavir to markedly decrease the exposure and antiplatelet effect of clopidogrel active
metabolite. The results from the fourth study indicated that dasabuvir is a highly sensitive and specific
CYP2C8 substrate and that combining clopidogrel with dasabuvir, or ritonavir with clopidogrel, may risk
patient safety. In the fifth study, clopidogrel significantly inhibited, and gemfibrozil almost completely
prevented, the CYP2C8-mediated biotransformation of desloratadine to its 3-hydroxy metabolite,
strongly suggesting that CYP2C8 is a crucial enzyme in desloratadine metabolism in vivo.
In conclusion, this work provides several findings that are applicable to patient care and drug research.
Most importantly, clopidogrel is a clinically relevant CYP2C8 inhibitor capable of causing potentially
hazardous DDIs, and it can be employed as a selective index inhibitor of CYP2C8 in clinical DDI studies.
Furthermore, dasabuvir can be applied as a CYP2C8 index substrate in subtherapeutic doses in clinical
drug research. Moreover, the observations from this work corroborate the ability of ritonavir to disrupt
CYP3A4-mediated bioactivation of prodrugs, including clopidogrel, which can compromise patient
safety. Finally, these results highlight the ability of glucuronide metabolites to act as substrates and
inhibitors of CYP enzymes, especially CYP2C8, and therefore they must be considered as potentially
interacting compounds during drug development.
9INTRODUCTION
Atherothrombotic events emerge as complications of atherosclerosis and are among the leading causes
of death worldwide (Laslett et al. 2012). According to European data from 2015, of the total deaths due
to all causes, coronary heart disease and stroke caused 19% and 9% among males, and 20% and 14%
among females, respectively (Townsend et al. 2016). The rupture of an atherosclerotic plaque initiates
a cascade that leads to platelet-rich thrombus formation that potentially causes ischemia in tissues distal
to the lesion. Clopidogrel attenuates this process by inhibiting platelet aggregation by antagonizing the
adenosine diphosphate (ADP) receptor subtype P2Y12 via its active cis-5-thiol metabolite (Bristol-Myers
Squibb/ Sanofi Pharmaceuticals 2018, Farid et al. 2010). Only under 10% of ingested clopidogrel is
activated in two steps primarily by cytochrome P450 (CYP) 2C19 and CYP3A4 enzymes, and
consequently, the bioactivation of clopidogel is susceptible to changes in CYP2C19 and CYP3A4 activity
due to genetic factors and drug-drug interactions (DDIs) (Figure 1) (Farid et al. 2010, Gilard et al. 2008,
Holmberg et al. 2014, Simon et al. 2009). However, the impact of the strong CYP3A4 inhibitor ritonavir
on clopidogrel bioactivation has been investigated only in small groups of patients on concomitant and
potentially interacting medications (Marsousi et al. 2018, Metzger and Momary 2014). Furthermore,
approximately 85–90% of clopidogrel is hydrolyzed by the polymorphic carboxylesterase (CES) 1 enzyme
to inactive carboxylic acid intermediate (Hagihara et al. 2009, Tang et al. 2006, Tarkiainen et al. 2015),
which is a substrate for uridine 5’-diphospho-glucuronosyltransferase (UGT) 2B enzymes that form a
secondary acyl-?-D-glucuronide metabolite (Figure 1) (Ji et al. 2018, Kahma et al. 2018).
In 2012, a pharmacoepidemiological study associated the concurrent use of clopidogrel with the
increased risk for myotoxic adverse events of cerivastatin, which is a substrate of CYP2C8 and organic
anion-transporting polypeptide (OATP) 1B1, a hepatic uptake transporter (Floyd et al. 2012, Shitara et
al. 2004). Furthermore, clinical studies have shown that clopidogrel increases the area under
concentration-time curve (AUC) of rosuvastatin (Pinheiro et al. 2012, Remsberg et al. 2013), an
OATP1B1 substrate that is not significantly metabolized (Neuvonen et al. 2006). In a more recent study,
clopidogrel augmented the exposure of the CYP2C8, OATP1B1, and CYP3A4 substrate repaglinide, and
in vitro and in silico experiments identified clopidogrel acyl-?-D-glucuronide as a mechanism-based
CYP2C8 inhibitor (Figure 1) (Tornio et al. 2014). Furthermore, clopidogrel has been shown to inhibit
OATP1B1 and to a lesser extent CYP3A4 in vitro (Floyd et al. 2012, Tamraz et al. 2013, Tornio et al. 2014).
Physiologically based pharmacokinetic (PBPK) simulations suggested OATP1B1 inhibition to
complement CYP2C8 inhibition in the clopidogrel-repaglinide DDI in humans (Tornio et al. 2014).
However, the clinical CYP2C8 and OATP1B1 inhibition potency of clopidogrel has required further clinical
investigation.
The fibric acid derivative gemfibrozil is applied as a hypolipidemic agent, and its primary 1-O-glucuronide
metabolite acts as mechanism-based inhibitor of CYP2C8 (Ogilvie et al. 2006), which almost completely
obliterates the enzyme activity in common clinical doses of 600 mg b.i.d. (Honkalammi et al. 2012).
Therefore, regulatory authorities recommend gemfibrozil as an index CYP2C8 inhibitor for clinical DDI
studies (EMA 2012, FDA 2017a). However, gemfibrozil markedly diminishes the activity of OATP1B1
(Tornio et al. 2017), which poses limitations for data interpretation if the victim drug under examination
is also a substrate of OATP1B1, such as repaglinide. Therefore, alternative CYP2C8 index inhibitors of
high enzyme selectivity are needed, and clopidogrel is suggested due to its DDI profile.
Simvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, the
metabolism of which is mainly mediated by CYP3A4, whereas the role of CYP2C8 in its metabolism is
less important (Lilja et al. 1998, Neuvonen et al. 1998, Prueksaritanont et al. 1997, Prueksaritanont et
al. 2003). Furthermore, its active metabolite, simvastatin acid, is highly sensitive to alterations in
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OATP1B1 activity (Niemi et al. 2011, Pasanen et al. 2006). Due to its pharmacokinetic profile, simvastatin
is an excellent index substrate for determining whether a potential perpetrator disturbs the activity of
OATP1B1 or CYP3A4. As clopidogrel was suggested to inhibit OATP1B1 and CYP3A4 (Tornio et al. 2014),
the objective of Study I was to examine the effect of clopidogrel in simvastatin pharmacokinetics.
Figure 1. Biotransformation pathways of clopidogrel, and the chemical structures of parent clopidogrel
and its 2-oxo-, active cis-5-thiol, carboxylic acid, and acyl-?-D-glucuronide metabolites. CES1,
carboxylesterase 1; CYP, cytochrome P450; MBI, mechanism-based inhibition; UGT, uridine 5’-
diphospho-glucuronosyltransferase.
Pioglitazone is a glucose-lowering agent of thiazolidinedione class that establishes its effect via
peroxisome proliferator-activated receptor (PPAR) ? agonism (Waugh et al. 2006). CYP2C8 is responsible
for both the biotransformation of pioglitazone to its major primary hydroxyl metabolite and for the
further conversion to secondary keto metabolite, whereas other enzymes participate in pioglitazone
metabolism only to a minor extent (Eckland and Danhof 2000, Jaakkola et al. 2005, Jaakkola et al.
2006a). Consistently, gemfibrozil has raised pioglitazone exposure approximately 3–5-fold, of which the
highest average increases have been observed in carriers of the CYP2C8*3 allele (Aquilante et al. 2013,
Deng et al. 2005, Jaakkola et al. 2005). Due to the crucial role of CYP2C8 in the metabolism of
pioglitazone, it can be applied as a CYP2C8 probe substrate, especially when considered that
transporter-related mechanisms do not significantly participate in its disposition (Backman et al. 2016).
Accordingly, Study II aimed to characterize the CYP2C8 inhibition potency of clopidogrel by examining
its effect on pioglitazone pharmacokinetics.
Prasugrel belongs to the same thienopyrimidine class of ADP receptor antagonists as clopidogrel, and
its platelet inhibition is mediated by the sequentially formed active metabolite that binds irreversibly to
the P2Y12 receptor (Farid et al. 2007). In contrast to clopidogrel, the CYP2C8 inhibition potential of
prasugrel has not been examined in a clinical setting. As polypharmacotherapy is common in patients
using clopidogrel or prasugrel, which have similar indications (Wiviott et al. 2007), comparing the
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CYP2C8-inhibitory effect of clopidogrel to that of prasugrel provides clinically relevant data. Study III
aimed to elaborate this matter by investigating how clopidogrel and prasugrel affect the
pharmacokinetics of montelukast, which has been considered as a sensitive CYP2C8 substrate, as
previously demonstrated by the ~4.5-fold increases in its exposure by gemfibrozil (Karonen et al. 2010,
Karonen et al. 2012). Moreover, other mechanisms, such as inhibition of OATP1B1-mediated hepatic
uptake, have been suggested to contribute to gemfibrozil-montelukast DDI (Varma et al. 2017), thereby
requiring further elucidation of montelukast pharmacokinetics.
Dasabuvir is a nonstructural protein 5B inhibitor used as a component of a ritonavir-containing 3-direct-
acting antiviral (3D) regimen in the treatment of hepatitis C virus (HCV) genotype 1 infection (Deeks
2015). The DDI profile of dasabuvir has been characterized in combination with the other drugs in 3D
regimen (Menon et al. 2015, Polepally et al. 2016), but it has been individually understudied in vivo.
Without ritonavir, the contribution of CYP2C8 and CYP3A4 in dasabuvir metabolism averages ~60% and
~30% in vitro, respectively, and the former is responsible for the formation of the tert-butyl hydroxyl
metabolite (M1), the major metabolite in human plasma (King et al. 2017, Shebley et al. 2017a, Shen et
al. 2016). When dasabuvir and ritonavir are administered concurrently in vivo, the metabolism of
dasabuvir is highly CYP2C8-selective, which gemfibrozil exemplified by causing a ~11-fold increase in
dasabuvir exposure (King et al. 2017, Menon et al. 2015, Polepally et al. 2016). Due to the increased risk
of adverse events of dasabuvir, such as decreased hemoglobin levels and suggested potential for QTc
prolongation, its concomitant administration with strong CYP2C8 inhibitors is contraindicated (FDA
2014a). Despite the unelucidated in vivo pharmacokinetics of dasabuvir, its DDI profile suggests that it
could be applied as a CYP2C8 index substrate. Therefore, Study IV intended to examine the effect of
clopidogrel on dasabuvir pharmacokinetics with and without ritonavir, while simultaneously
characterizing the effect of ritonavir in clopidogrel pharmacokinetics and antiplatelet effect.
Desloratadine is a second-generation histamine H1 receptor antagonist indicated for the treatment of
allergic rhinitis and chronic urticaria (FDA 2014c). In vitro, the formation of the major 3-hydroxy
metabolite of desloratadine is highly dependent on CYP2C8 activity (Kazmi et al. 2015), but this finding
has not been confirmed in clinical studies. The benign safety profile of desloratadine and proposed
crucial role of CYP2C8 in its metabolism suggest that desloratadine could be utilized as a CYP2C8 probe
substrate. In order to compare the CYP2C8 inhibition strength of clopidogrel with that of gemfibrozil,
and to explore the contribution of CYP2C8 in desloratadine metabolism in vivo, Study V examined
whether concurrent administration of clopidogrel or gemfibrozil could affect desloratadine
pharmacokinetics.
This work includes five clinical pharmacokinetic DDI studies performed in randomized, controlled,
crossover settings. The studies were primarily conducted in order to characterize the DDI mechanisms
and profile of clopidogrel, and their implications for drug research. Furthermore, the secondary targets
were to reveal important DDIs caused by clopidogrel, and to search for potential CYP2C8 index
substrates.
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REVIEW OF THE LITERATURE
1. Pharmacokinetics
The human body considers drugs to be xenobiotics, that is, foreign molecules or atoms.
Pharmacokinetics examines how drugs are absorbed, distributed, metabolized, and eventually
eliminated from the organism (Rowland and Tozer 2011). Every drug proves useless, if it cannot reach
target tissues in required amounts to present its desired physiologic effects, i.e., “pharmacodynamics”,
or it accumulates in other tissues and causes unacceptable toxicity. Pharmacokinetic events often take
place simultaneously and are affected by disease, age, organ function, body composition, sex, ethnicity,
and numerous other factors. Therefore, it is crucial to study drug behavior in different populations. In
vitro experiments, PBPK and other in silico modeling are preeminent procedures in studying compound
properties, such as absorption, distribution, elimination, toxicity, and affinity to enzymes or transporters
(FDA 2017b, Raunio et al. 2015). Only if these vital methods imply that safety and efficacy requirements
are fulfilled, drug behavior can continue on to be studied in animals, and finally in humans. In order to
give marketing authorization, regulatory authorities require pharmaceutical compounds to possess an
adequate risk-benefit ratio, which includes a reasonable therapeutic window (EMA 2012, FDA 2017a).
Of note, theories of sufficient practicality are prone to making oversimplifications when characterizing
the complexities of physiological events, and pharmacokinetic theories are no exception.
Ingested drugs require absorption from the gastrointestinal (GI) tract that can take place by passive
diffusion, transporter protein mediated uptake, or their combination. In contrast, efflux transporters
can prevent xenobiotics from entering the body, or they may facilitate drug elimination to bile or urine,
for example. The liver is the paramount organ in drug metabolism, but in certain cases,
biotransformation begins already in the intestinal epithelial cells. Furthermore, some metabolic
enzymes are expressed in significant quantities in other organs, such as the kidneys and the lungs
(Hukkanen et al. 2002, Knights et al. 2013). Some drugs reach systemic circulation only in trace amounts,
i.e., have low oral bioavailability, which can be caused by poor passive absorption, and transport and
metabolic systems of the intestine and the liver. Even a drug with a low oral bioavailability can have
metabolites that generate significant systemic exposure when released from hepatocytes, for instance.
Drug metabolites are often physiologically inactive, but can also have their own pharmacologic effects.
In addition, they may disturb enzyme and transporter protein activity or cause toxicity. Thus,
investigating only the properties of the parent compound is insufficient to thoroughly characterize the
net effect of a drug.
Primary pharmacokinetic variables, whereof other variables are derived, include clearance (CL), volume
of distribution (Vd), bioavailability, and absorption rate. However, when reporting the physiological
behavior of a drug, the most important pharmacokinetic parameters are AUC that reflects drug
exposure, maximum concentration (Cmax), elimination half-life (t½), and time to reach Cmax (tmax). When
examining the pharmacokinetics of a drug administered as a single dose, its AUC extrapolated to infinity
(AUC0-?) corresponds to the dose interval AUC in steady-state conditions, if the drug exhibits linear
pharmacokinetics. Therefore, AUC0-? is used as a standard pharmacokinetic parameter when describing
drug exposure. Furthermore, several additional variables are often applied in describing
pharmacokinetics, e.g., fraction metabolized by a certain enzyme (fm), elimination rate constant (ke) that
is employed when determining t½, and unbound fraction (fu). In addition, it should be noted that the
pharmacokinetic properties of a drug metabolite may radically differ from those of the parent drug.
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1.1 Drug-drug interactions
Pharmacokinetic DDI is defined as an event where one drug called the “perpetrator” alters the
absorption, distribution, metabolism, or elimination of a “victim” drug. Furthermore, concurrent
administration of drugs with a similar or opposite pharmacodynamic profile often leads to potentiating
synergism or abrogation of therapeutic response, respectively, which can have similar manifestations
as pharmacokinetic DDIs. They can lead to increased risk of adverse reactions or diminished therapeutic
efficacy, and especially if unrecognized, DDIs may increase mortality and morbidity, and burden
healthcare services. Improved patient diagnostics and drug treatments, as well as population ageing,
augment the prevalence of pharmaceuticals use. Polypharmacotherapy is a common practice, especially
in patients with multiple medical conditions, which in turn may predispose individuals to relevant DDIs.
Therefore, studying DDIs is paramount for improving patient safety.
Absorption can be interfered with, for example, by affecting the pH of the GI tract, which can modify
the ionization ratio of another drug, as exemplified by the effect of proton pump inhibitors on rilpivirine
pharmacokinetics (FDA 2011). A striking example of altered absorption kinetics is how activated
charcoal binds to the majority of drugs and almost completely prevents them from entering the body
(Rowland and Tozer 2011). Drug-induced changes in transporter protein function can modify all the
aforementioned pharmacokinetic processes, depending on the location of the transporter (Shitara et
al. 2006), which is discussed in more detail in section 5. Excluding transporter-mediated mechanisms,
clinically relevant DDIs emerging from altered drug distribution are uncommon; however, the effects of
certain chelating agents on the disposition of metals provide an example of this phenomenon (Andersen
and Aaseth 2016). The majority of important DDIs are caused by changes in drug metabolism that result
from enzyme inhibition or induction (Wilkinson 2005). Several mechanisms (e.g., competitive,
uncompetitive, noncompetitive, quasi-irreversible, and reversible) of enzyme inhibition exist, but
categorizing enzyme inhibition in a certain class can be challenging, because empirical observations on
enzyme kinetics do not always fit in distinct theoretical models. Enzyme induction is predominantly
based on increased gene expression via transcription factor activation, but also diminished enzyme
degradation is considered to be an induction mechanism. Finally, drug elimination can be affected by
changes in the physicochemical characteristics of urine, or the enterohepatic circulation, for example
(Rowland and Tozer 2011).
When the DDI potential of a drug is evaluated, its abilities to act as a perpetrator or a victim drug must
be characterized. If the capability of a drug to inhibit or induce the function of an enzyme or a
transporter involved in drug disposition (i.e., to act as a perpetrator) is examined, a “probe” or “index”
substrate is usually applied as the victim drug (Tornio et al. 2019). An ideal index substrate should
possess dispositional qualities that are sensitive to alterations in the specific pharmacokinetic pathway
under examination, while having an adequate safety profile to ensure the safety of studied subjects.
Correspondingly, when the disposition mechanisms of a drug and its potential to act as a victim drug
are characterized, a (pre)treatment with an index inhibitor or inducer is commonly utilized (FDA 2017a).
Analogously to ideal index substrates, optimal index inhibitors or inducers should cause a strong and
specific change in the function of a transporter or an enzyme of interest, and they should have a benign
safety profile (EMA 2012). Consequently, the same pharmacokinetic qualities that make an ideal index
perpetrator or a victim drug can cause problems in patient care and may even lead to contraindications
in clinical practice, where dosage regimens often markedly differ from DDI studies.
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1.1.1. Mechanism-based inhibition
Mechanism-based inhibition (MBI) is broadly defined as a process where the catalytic machinery of the
enzyme converts an enzyme substrate to a reactive species that inactivates the enzyme before leaving
the active site (Silverman 1995). Commonly, MBI is irreversible due to the covalent nature of the bond
formed between the enzyme active site and the reactive intermediate, but slowly reversible reactions
and non-covalent pairings have also been reported (Silverman and Hoffman 1984). More specifically,
seven original criteria have been established to characterize MBI of enzymes: (i) the inhibition has to be
time-dependent, that is, the lost enzyme activity should increase over time and ideally exhibit pseudo
first-order kinetics; (ii) the rate of inactivation should saturate with respect to inhibitor concentration;
(iii) the presence of another substrate slows down the inhibition reaction; (iv) not including rare
exceptions, enzyme activity does not return upon dialysis or gel filtration; (v) the inactivation should
result in a 1:1 stoichiometry of labeling of the enzyme by the inactivator; (vi) catalytic transformation
by the targeted enzyme is an obligatory requirement for the creation of the reactive intermediate; and
(vii) enzyme inactivation takes place before release of the reactive species from the active site
(Silverman and Hoffman 1984, Silverman 1995). The first five criteria could be used to define any
inhibition process by covalent or tightly bound slow-binding non-covalent inhibitor, whereas the sixth
criterion is unique to MBI. In addition, MBI needs to involve nicotinamide adenine dinucleotide
phosphate (NADPH) as a cofactor, and the presence of added reactive species scavengers should not
interfere with the inhibition reaction (Fontana et al. 2005). It has been suggested that mechanism-based
inhibitors exhibit more pronounced enzyme specificity than competitive inhibitors due to the multiple
requirements imposed on them (Hollenberg et al. 2008). Moreover, immunological adverse reactions
and hepatotoxicity have been associated with drugs that cause MBI (Kalgutkar et al. 2007, Masubuchi
and Horie 2007).
Concerning human physiology, MBI causes practically permanent enzyme inactivation, and therefore
newly synthesized protein is required to restore enzymatic function. Therefore, the time needed to
reach baseline enzyme activity depends on the degradation half-life of the enzyme and on the degree
of net enzyme inactivation achieved by the inhibitor, which is dependent on the inhibitor exposure. The
MBI-related slow recovery rate of enzyme activity has important clinical implications, because the DDI
risk persists longer than in the case of competitive inhibition that is only dependent on the inhibitor
concentrations on the enzyme site at any given time. In addition to causing longer lasting risk of harmful
DDIs, this phenomenon can be beneficial when a mechanism-based inhibitor is applied as a
pharmacokinetic enhancer to achieve more infrequent dosing and consistent exposure of other drugs.
2. Pharmacogenomics
Many major drug classes exhibit vast variability in drug response and toxicity between individuals.
Instead of receiving the desired drug response, a marked proportion of patients shows only a partial
response or experiences adverse drug reactions. Plasma concentrations of a drug can vary substantially
between two individuals of the same weight using the same dose, as exemplified by the
pharmacokinetics of alfentanil, desloratadine, midazolam, nortriptyline, and paritaprevir (Eichelbaum
et al. 2006, Menon et al. 2017, Rowland and Tozer 2011). On average, genetics is estimated to account
for 15–30% of variability in drug metabolism and response, but for certain drugs, genetic factors can
explain up to 95% of the interindividual variation in disposition and response (Eichelbaum et al. 2006,
Evans and McLeod 2003). Even though knowledge regarding the impact of genetic variance on drug
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response has expanded enormously in recent years, a large fraction of inherited pharmacokinetic and
pharmacodynamic traits remain uncharacterized.
Pharmacogenomics studies the differences in drug response owing to genetic variation and gene
expression, while its subset pharmacogenetics examines the relation of deoxyribonucleic acid (DNA)
sequence variations and drug response (EMA 2007). Several genetic variants have already been
determined to pronouncedly affect drug response, but the significance of interindividual differences in
gene expression is still understudied. “Genetic polymorphism” is defined as the occurrence in the same
population of two or more alleles at one locus, each with appreciable frequency (traditionally at least
1%) (Cavalli-Sforza and Bodmer 1971). Despite the fact that the terms “variation” and “polymorphism”
are often used interchangeably, the former is currently preferred due to the lack of allele frequency
limitations that concern the latter, especially when single nucleotide variations (SNVs) are discussed.
Variation in DNA sequence encoding drug targets, transporters, metabolizing enzymes, can significantly
contribute to variability in drug response between individuals (Evans and Relling 1999). This applies not
only to variation in the DNA sequence of normal tissues but also to changes seen in tumor DNA, which
can predict responses to antineoplastic treatments. Aside from human genomic traits, the genomics of
pathogens can also affect drug responses in the form of antimicrobial resistance, for example (Hughes
and Andersson 2015).
The link between heritable traits and altered drug response was first elucidated in the 1950s when
primaquine-induced hemolysis was found to be more common in populations with a high prevalence of
glucose-6-phosphate deficiency (Beutler 1969), and when prolonged suxamethonium-induced muscle
relaxation was associated with inherited low plasma pseudocholinesterase (butyrylcholinesterase)
activity (Lehmann and Ryan 1956). Concurrently, isoniazid metabolism and adverse effects were found
to have hereditary characteristics (Evans et al. 1960). In the early 2000s, biotechnological advancements
and the sequencing of the human genome caused an exponential increase in pharmacogenomics
research (Lander et al. 2001). Contemporarily, a wide array of specific genetic variations have been
associated with differences in drug response, e.g., CYP2D6 genotype and response to various
antidepressants, or analgesia and toxicity produced by codeine and tramadol (Eichelbaum et al. 2006,
Ingelman-Sundberg et al. 2007); however, routine applications of this knowledge remain scarce. To be
accepted as standard of care, clinical implementations of pharmacogenomics must meet the criteria of
analytical validity, and clinical validity and utility (Relling and Evans 2015). These matters have been
addressed by clinical guidelines on how to implement pharmacogenomics knowledge in order to
improve treatment outcomes (Relling and Klein 2011), and pharmacogenomics testing is likely to be
widespread in clinical practice in the not-so-distant future when the amount, availability, validity, and
costs of the tests reach sufficient levels.
DNA sequence variation can vary from SNVs to gene copy-number variations and chromosomal
reorganization (Feuk et al. 2006), and epigenetic modifications include DNA methylation and
hydroxymethylation, noncoding RNA-mediated gene regulation, histone modification, and changes in
nucleosome positioning (Huang et al. 2014). Genomic variation can influence gene expression and alter
phenotype in multiple ways; however, a large portion of genomic variation related to drug response is
considered to have almost neutral phenotype effects (Sadee and Dai 2005). DNA sequence variation
may have phenotype effects by altering gene expression regulation, mRNA stability and processing
(including splicing), and protein structure and function, for example. Furthermore, genetic variation can
cause augmented levels of a translated protein, which in turn may lead to accelerated drug metabolism,
as is the case with the CYP2C19*17 allele and various CYP2C19 substrates (Sim et al. 2006). Nucleotide
sequence variations may also create a functionally deficient enzyme, or it can decrease the level of
metabolic enzyme expression that may raise both the drug concentrations and risk of toxicity. For
example, certain DPYD variants are associated with increased exposure of fluoropyrimidines and
probability of their toxic effects (Amstutz et al. 2018, Henricks et al. 2018, Meulendijks et al. 2015).
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Moreover, interindividual differences in drug response can take place via genetic variation that results
in alternative forms of a pharmacodynamic target, as demonstrated by certain VKORC1 variants and
warfarin resistance (Rost et al. 2004), and CFTR genotype and ivacaftor response (Accurso et al. 2010).
In addition, variation in DNA sequence can have profound effects on drug response that are unrelated
to the pharmacodynamic and pharmacokinetic characteristics of a drug. For example, many
immunologic adverse drug reactions are strongly associated with certain HLA alleles (Redwood et al.
2018).
3. Phase I metabolism
Most drugs are relatively lipophilic, which facilitates their penetration across biological membranes but
also limits their elimination. Thus, many drugs require biotransformation to a more hydrophilic form to
be efficiently excreted from the body. Furthermore, some drugs, such as clopidogrel and prostaglandin
(PG) analogs used to treat glaucoma (Bean and Camras 2008, Farid et al. 2010), are prodrugs, that is,
without inherent pharmacological efficacy, and they need to be bioactivated often via same enzymatic
pathways that facilitate the elimination of xenobiotics. Commonly, the first step in drug metabolism
creates a functional group in the molecule, for example via oxidation, reduction, hydrolyzation, or
hydration reaction by one or several enzymes, such as cytochrome P450 (CYP), esterases, and amine
oxidases. These processes are traditionally categorized under the term “phase I metabolism”. The
resulting metabolite usually acts as an intermediate for the next metabolic stage. However, dividing
drug metabolism into distinct stages is imprecise, because it falsely implies a universal sequentiality in
metabolic events (Josephy et al. 2005).
3.1. Cytochrome P450 enzymes
CYPs were discovered in the 1950s when cytochrome pigments were isolated from rabbit liver
microsomes, and their light absorption peak wavelength was measured at 450 nm, when bound to
carbon monoxide (Klingenberg 1958). Accordingly, a few years later they were labeled as “cytochrome
P450” hemoproteins (Omura and Sato 1962). The CYP superfamily deserves special attention, because
it accounts for approximately 75% of drug clearance (Guengerich 2008, Wrighton and Stevens 1992).
Furthermore, CYPs play a key role in the mitochondrial electron transfer chain (Hannemann et al. 2007),
and they participate in the metabolism of several endogenous substances, such as steroid hormones
and eicosanoids (Rendic and Di Carlo 1997). CYPs are highly abundant and are found in most eukaryotic
and prokaryotic cells, and even in some viruses (Lamb et al. 2009). Those CYPs that participate in drug
metabolism are transmembrane proteins located in the smooth endoplasmic reticulum with their active
site on the cytosolic side of the membrane (Cribb et al. 2005). While the great majority of CYPs catalyze
oxidative reactions (Guengerich 2001), some also catalyze uncommon reactions, such as reduction,
complex dimerization, and ring formation (Isin and Guengerich 2007). As CYPs predominantly add a
functional group on their substrate molecules, the CYP-mediated reactions are suspected to more often
produce a species that can act as a mechanism-based enzyme inhibitor, when compared to reactions
by most other enzymes. Quantitatively, CYPs involved in drug metabolism are mainly expressed in the
liver but can also be found in large variety of extrahepatic tissues, especially the small intestine (Ding
and Kaminsky 2003). The protein structure of many CYPs is highly adaptive, and their active site cavities
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are able to change their size and conformation depending on the ligand they are accommodating
(Ekroos and Sjogren 2006, Zhao et al. 2006).
In humans, 57 functional genes are identified to encode individual CYP enzymes, which are subsumed
under 18 families and 42 subfamilies based on their amino acid sequence (Nebert and Russell 2002,
Nelson et al. 2004). All CYPs have the same heme complex as the catalytic center (Meunier et al. 2004),
but the amino acid sequence is ? 40% similar between CYP family members and ? 55% similar between
members of subfamilies (Nelson et al. 2004). In addition to genetic differences, multiple other factors
including age, sex, body weight, and disease, explain the marked interindividual variability in enzyme
activity exhibited by many CYPs (Tracy et al. 2016). Due to the increased risk of diminished efficacy or
adverse reactions, dosing sensitive substrates of polymorphic CYPs is problematic, especially if the
substrate has a narrow therapeutic index. Therefore, CYP genotyping is recommended when prescribing
numerous drugs (Tornio and Backman 2018). In particular, CYP2C19, CYP2C9, and CYP2D6 are highly
polymorphic, whereas variant alleles leading to diminished enzyme activity of clinical relevance are rare
in CYP1A2 and CYP2E1 (Ingelman-Sundberg et al. 2007, Zanger and Schwab 2013, Zhou et al. 2017). It
should be noted, however, that although CYP pharmacogenomics has been investigated intensively, a
marked share of inherited variance in CYP activity is still inexplicable. For example, CYP3A4, the most
important CYP enzyme in xenobiotic metabolism, demonstrates a vast variance in activity between
individuals. CYP3A4 harbors the *22 allele that results in decreased metabolism of several CYP3A4
substrates, but it accounts for only a small portion of heritable variation in CYP3A4 activity, which cannot
be explained by other known CYP3A4 variants, either (Zanger and Schwab 2013). Furthermore,
functional consequences of many identified CYP SNVs or haplotypes are yet undetermined.
Most of the known clinically relevant DDIs are CYP-mediated, and therefore drugs under development
are routinely screened for potential to act as CYP substrates, inhibitors, or inducers (FDA 2017a). The
United States Food and Drug Administration (FDA) states that strong, moderate, and weak CYP inhibitors
are compounds that increase the AUC of a sensitive probe substrate by ? 5-fold, ? 2- to < 5-fold, and ?
1.25- to < 2-fold, respectively (FDA 2017a). This classification is somewhat problematic as some enzymes
(e.g., CYP2B6) lack sensitive index or probe substrates, or because the probe substrate may have
additional disposition mechanisms.
3.1.1. Cytochrome P450 2C8
CYP2C8 contributes to 6–7% of total hepatic CYP content (Rostami-Hodjegan and Tucker 2007, Totah
and Rettie 2005), and it is also expressed in the small intestine, kidneys, and adrenal glands, for example
(Klose et al. 1999, Lapple et al. 2003). CYP2C8 is the most abundant hepatic CYP2C isoenzyme during
prenatal development (Johansson et al. 2014), and its expression reaches adult levels in early childhood
(Naraharisetti et al. 2010). Although the amino acid sequence of CYP2C8 is about 74% identical to those
of CYP2C19 and CYP2C9, these CYP2C isoenzymes have largely distinct substrate specificities (Chen and
Goldstein 2009, Johnson and Stout 2005, Ridderström et al. 2001). The expression of CYP2C8 is
regulated by multiple transcription factors including constitutive androstane receptor (CAR), pregnane
X receptor (PXR), glucocorticoid receptor (GR), vitamin D receptor (VDR), and hepatocyte nuclear factor
(HNF) 4? (Ferguson et al. 2005). Concerning DDIs, CAR and PXR are the most important routes of CYP2C8
induction by xenobiotics. Dimeric CYP2C8 has a molecular weight of 110 kDa (Schoch et al. 2004), and
its degradation half-life is approximated to 22 hours (Backman et al. 2009). The active site cavity is
trifurcated and large in volume, which explains its capability to accommodate structurally diverse
molecules (Schoch et al. 2008).
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CYP2C8 contributes to the metabolism of more than 100 clinically applied drugs (Backman et al. 2016).
It has a major role in the biotransformation of a host of widely used drugs including amodiaquine,
dasabuvir, enzalutamide, ibuprofen, montelukast, paclitaxel, pioglitazone, repaglinide, and selexipag
(Backman et al. 2016, Bruderer et al. 2017). In addition, several drugs, e.g., desloratadine, diclofenac,
and estradiol, have glucuronide metabolites that are substrates of CYP2C8 (Delaforge et al. 2005, Kazmi
et al. 2015, Kumar et al. 2002). Contemporarily, repaglinide is the CYP2C8 index substrate for in vivo and
in vitro studies most often recommended by the European and American regulatory authorities (EMA
2012, FDA 2017a, FDA 2017b). However, the hypoglycemia-inducing potential and additional disposition
mechanisms (OATP1B1-mediated hepatic uptake and metabolism by CYP3A4) of repaglinide limit its
practicality as a CYP2C8 probe substrate (Niemi et al. 2003, Niemi et al. 2005), and thus an urge for
more specific and safe CYP2C8 index substrates exists. Besides repaglinide, cerivastatin and estradiol
17-?-glucuronide are also dual substrates of CYP2C8 and OATP1B1 (Kanai et al. 1996, Muck 1998).
Gemfibrozil and clopidogrel are the recommended index CYP2C8 inhibitors for in vivo DDI studies, and
both have a glucuronide metabolite that acts as mechanism-based inhibitor of CYP2C8 (FDA 2017a,
Ogilvie et al. 2006, Tornio et al. 2014). Multiple drugs, for example candesartan cilexetil, zafirlukast, and
felodipine, markedly inhibit CYP2C8 in vitro (Walsky et al. 2005). However, they are unlikely to cause
clinically significant CYP2C8-mediated DDIs because candesartan cilexetil is rapidly systemically
hydrolyzed, while zafirlukast and felodipine are highly-bound to plasma proteins. These discordances
highlight the need for clinical studies when the DDI potential of different pharmacological compounds
is being evaluated.
In concomitant use, rifampicin, a CYP2C8 inducer mainly via PXR activation (Chen and Raymond 2006),
has decreased the exposure of several CYP2C8 substrates (Jaakkola et al. 2006b, Niemi et al. 2000, Niemi
et al. 2004). DDI studies between other CYP2C8 inducers and substrates are scarce, but phenobarbital,
a CAR activator, has caused a pronounced induction of CYP2C8 in vitro (Madan et al. 2003).
The CYP2C8 *2, *3, and *4 alleles account for most of the nonsynonymous variance in the CYP2C8 gene
(Backman et al. 2016). Depending on the substrate, a CYP2C8 polymorphism can have different or even
opposite effects in drug clearance. For example, the CYP2C8*3 allele has been associated with
decreased exposure of rosiglitazone and repaglinide (Aquilante et al. 2008, Niemi et al. 2005), whereas
the same allele has been associated with lower ibuprofen and paclitaxel clearance (Garcia-Martin et al.
2004) and increased risk for paclitaxel-induced neurotoxicity in ovarian and breast cancer patients
(Green et al. 2011, Hertz et al. 2013). The frequency of the CYP2C8 alleles associated with decreased
enzyme activity (expressed as decreased paclitaxel clearance) varies between major populations ranging
from < 1% in East Asians to 17.2% and 19.2% in Africans and Europeans, respectively (Zhou et al. 2017).
Currently, no consensus guidelines are established for implementing pharmacogenomic CYP2C8 testing.
4. Phase II metabolism
In general, phase II metabolism refers to a metabolic process where a charged species such as glucuronic
acid, sulfate, glycine, or glutathione, is conjugated to a drug or its metabolite producing a compound
that is usually more easily eliminated from the body than the original species. Examples of enzymes
involved in phase II metabolism include sulfotransferases, glutathione S-transferases, and
methyltransferases. Many drugs require no preceding biotransformation by a phase I enzyme and can
be directly subject to phase II metabolism, as exemplified by the metabolism of lorazepam, lamotrigine,
and morphine (Guillemette et al. 2014). Furthermore, phase II metabolites can possess their own
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pharmacological activity (Paul et al. 1989), cause toxicity (Spahn-Langguth and Benet 1992), or be
further metabolized (Delaforge et al. 2005, Ingelman-Sundberg et al. 1975).
4.1. Uridine 5’-diphospho-glucuronosyltransferase enzymes
UGTs form a crucial enzyme superfamily in phase II metabolism (Ritter 2000). They catalyze covalent
bonding of a functional group in a substrate molecule and a glucuronic acid residue from the cofactor
uridine 5’-diphosphate (UDP) glucuronic acid yielding solely ?-D-glucuronides (Rowland et al. 2013),
excluding rare cases when they conjugate other sugar residues (Mackenzie et al. 2003, Senafi et al.
1994). UGTs govern the inactivation of nearly 35% of the drugs currently on the market (Guillemette et
al. 2014), and a large variety of their substrates are related to their ability to catalyze the addition of a
glucuronic acid residue to multiple functional sites, such as amine, hydroxyl, carboxyl, and sulfuryl
groups (Radominska-Pandya et al. 1999). Contemporary classification divides the 19 functional UGTs
into two families, UGT1 and UGT2, with the latter being further subdivided to UGT2A and UGT2B
(Guillemette et al. 2014). UGTs are closely related two other UDP-glycosyltransferase families, UGT3
and UGT8, which consist of enzymes that catalyze the conjugation of glycosyl residues other than
glucuronic acid (Mackenzie et al. 2005). The members of the UGT families share more than 50% amino
acid sequence identity to each other, but less than 50% to members of other families, and subfamily
members share > 60% sequence homology (Burchell et al. 1991). Mature UGTs are transmembrane
proteins of about 505 amino acid residues that are found almost exclusively in the endoplasmic
reticulum (Radominska-Pandya et al. 2005), and they exist mostly as oligomers (Meech and Mackenzie
1997a, Radominska-Pandya et al. 2005). The luminal domain consists of about 95% of the peptide chain,
while the transmembrane and cytosolic domains include 17 and about 20 amino acid residues,
respectively (Radominska-Pandya et al. 2005). The carboxyl terminal end of UGTs is conserved, which
has led to the suggestion that this domain binds to the cofactor UDP-glucuronic acid common to all UGT
isoforms (Meech and Mackenzie 1997b). The hypothesis has been corroborated by the determination
of the UGT2B7 crystal structure (Miley et al. 2007, Radominska-Pandya et al. 2010); however, the crystal
structures of other UGT isoenzymes remain unsolved (Fujiwara et al. 2016). UGTs are mainly expressed
in the liver and some isoforms are found in the intestinal epithelium, but various other tissues express
UGTs in smaller quantities (Stingl et al. 2014). The UDP-glucuronic acid concentrations partly determine
the UGT activity in different tissues because they are below the Km of UGTs in many cell types (Ritter
2000).
Aside from xenobiotics, UGTs also metabolize endogenous substances such as bilirubin, steroid
hormones, and biliary acids (Guillemette 2003), and defects in UGT function can cause diseases, e.g.,
Crigler-Najjar syndrome (Wells et al. 2004). Furthermore, genetic variants that lead to altered UGT
activity may modify susceptibility to diseases and the aggressiveness of certain cancers, independent of
drug response (Guillemette et al. 2014). Although UGTs generally facilitate the elimination of endo- and
xenobiotics by forming a conjugate that is usually less reactive than the original species, certain
glucuronides possess biological activity. For example, morphine-6?-glucuronide is a more potent μ-
opioid receptor antagonist than parent morphine (Paul et al. 1989), and 3-glucuronides of
buprenorphine and its metabolite, norbuprenorphine, exhibit pharmacological activity distinct from the
parent compound (Brown et al. 2011). In addition, some glucuronides have been observed to cause
toxicity, or act as membrane transporter and enzyme inhibitors (Regan et al. 2010, Shitara et al. 2004,
Tornio et al. 2014). The proximity of UGTs and CYPs in the endoplasmic reticulum enables the interplay
of these enzymatic systems, and accordingly, if a glucuronide acts as a CYP inhibitor, its plasma
concentrations do not always reflect its concentrations at the enzyme site.
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In the liver, HNF1 is one of the key regulators of UGT expression (Mackenzie et al. 2005). Furthermore,
many UGTs and CYPs involved in xenobiotic metabolism share common induction mechanisms, for
example activation of aryl hydrocarbon receptor (AhR), CAR, and PXR (Hu et al. 2014, Lin 2006, Yang et
al. 2017), which provides another demonstration of the functional interconnectedness of the two
enzyme superfamilies. The amount of known and relevant drug interactions mediated by UGT-involved
mechanisms is substantially smaller than that by CYP-related mechanisms (Kiang et al. 2005, Lin and Lu
1998). Examples of clinically important UGT-mediated DDIs include alterations in lamotrigine
glucuronidation by the UGT inhibitor valproate or UGT-inducing antiepileptics that require dosage
adjustments of lamotrigine, when used concurrently (Perucca 2006, Yuen et al. 1992). In general, when
contrasted with common CYP variants, important common UGT variants are rare (Stingl et al. 2014).
Among the most clinically relevant UGT variants are the UGT1A1 alleles leading to decreased enzyme
activity that are associated with the increased risk for irinotecan-induced toxicity in colorectal cancer
treatment (Liu et al. 2014), and hyperbilirubinemia by antiretroviral protease inhibitor atazanavir
(Gammal et al. 2016).
5. Membrane transporters
Facilitated or active transport mechanisms can complement passive diffusion in assisting the movement
of endobiotics and drugs through biological membranes, sometimes even against concentration
gradients. Membrane transporters can participate in protecting the whole organism, or specific
vulnerable tissues or pharmacokinetic compartments, e.g., the central nervous system and fetus when
expressed in blood-brain barrier and placenta, respectively. In the human genome, approximately 2,000
genes encode transporter proteins, which reflects the importance of transporter function in cellular and
systemic homeostasis (Brunton et al. 2006).
Membrane transporters can be categorized in several ways, for example to influx and efflux
transporters, or based on their energy source or transmembrane structure, e.g., adenosine triphosphate
binding cassette (ABC) or solute carrier (SLC) transporters, respectively (He et al. 2009, Hediger et al.
2013, Jones and George 2004). Influx transporters facilitate cellular drug uptake, and they include
organic anion transporters (OATs), organic cation transporters (OCTs), and OATPs. In contrast, efflux
transporters are involved in moving different compounds out of cells, and moreover, their increased
expression can contribute to resistance against antineoplastic agents, and against antimicrobials when
localized in microbial membranes. Clinically important efflux transporters include P-glycoprotein or
multidrug resistance protein 1 (P-gp or MDR1), the multi-drug resistance-associated proteins (MRPs),
multidrug and toxin extrusion proteins (MATEs), and breast cancer resistance protein (BCRP). In the
liver, most efflux transporters are expressed in the canalicular membranes, but certain MRP
transporters are located in the sinusoidal membranes where they are thought to export compounds to
the bloodstream for urinary elimination (Gu and Manautou 2010).
One cell can express multiple transporter proteins, which in turn can have common substrates and
inhibitors (Giacomini et al. 2010). This complicates the evaluation of individual transporter participation
in pharmacokinetics based on in vivo data. Several transporter-related drug interactions of high clinical
significance exist and thus transporter contribution to drug disposition is contemporarily examined in
vitro and in vivo during drug development (EMA 2012, FDA 2017a, FDA 2017b). Regarding relevant
pharmacokinetic interactions, the most important transporters are located in the epithelium of the
small intestine, liver, and kidneys (Gessner et al. 2019). Moreover, genetic polymorphisms may
influence transporter activity and drug exposure, thereby altering the risk of adverse drug reactions and
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the magnitude of DDIs (Zolk and Fromm 2011). Membrane transporters can also act as drug targets, of
which the inhibition of the serotonin transporter by antidepressants provide one the most prominent
examples (Coleman et al. 2016).
5.1. Organic anion transporting polypeptide 1B1
Organic anion transporting polypeptide (OATP) 1B1 is a transporter protein that is expressed on the
basolateral membrane of hepatocytes, where it facilitates the uptake of several compounds from portal
venous circulation (König et al. 2000). OATP1B1 consists of 691 amino acids with a molecular weight of
~84 kDa (König et al. 2000), and the amino acid sequence of OATP1B1 is ~80% identical with that of
OATP1B3, the other member of the OATP1B subfamily (Hagenbuch and Meier 2003). Typical OATP1B1
substrates are anionic, amphipathic, and highly bound in albumin, with a molecular weight of > 350 Da
(Hagenbuch and Meier 2004). OATP1B1 contributes to hepatic uptake of several endogenous
substances, such as bile salts, bilirubin, eicosanoids, and steroid conjugates (Hagenbuch and Meier
2003, Xiang et al. 2009). In addition, it participates in the disposition of multiple drugs, such as
repaglinide, anticancer agent irinotecan, benzylpenicillin, methotrexate, bosentan, and many HMG-CoA
reductase inhibitors (statins) (Niemi et al. 2011).
The SLCO1B1 gene, which has over 45 identified nonsynonymous variants, encodes OATP1B1 (Lee and
Ho 2017), and its transcription is regulated by several transcription factors including HNF1, HNF3, FXR,
and PXR (Jung et al. 2001, Niemi et al. 2011). The coordinate regulation of CYPs, UGTs, and several
transporters including OATP1B1 (Congiu et al. 2009), reflects the importance of the interplay between
these physiological components in protecting the organism against chemical stressors. Rotor Syndrome,
an autosomal recessive disorder, is associated with certain rare coexisting SCLO1B1 and SLCO1B3
variants that lead to conjugated hyperbilirubinemia and coproporphynuria (van de Steeg et al. 2012).
The c.521T>C (rs4149056) SNV in exon 5 that produces p.Val174Ala substitution, leads to decreased
transport activity and membrane expression of OATP1B1 (Tirona et al. 2001). The frequency of this SNV
ranges from 1.9% in sub-Saharan populations to 24% in Native American populations (Pasanen et al.
2008), and it has substantial implications involving numerous drugs (Oshiro et al. 2010).
OATP1B1 inhibition is considered to be an important mechanism that contributes to many clinically
relevant DDIs, involving various OATP1B1 substrates, such as multiple statins, repaglinide, and bosentan
(Shitara 2011). According to current knowledge, no clinically relevant DDIs are caused solely by OATP1B1
induction. In primary human hepatocytes, the PXR agonist rifampicin induced SLCO1B1 mRNa levels 2.4-
fold (Jigorel et al. 2006). However, rifampicin also inhibits OATP1B1, as demonstrated by its augmenting
impact on the exposure of relatively sensitive and specific OATP1B1 substrate pitavastatin, when
rifampicin is administered in a single dose (Prueksaritanont et al. 2014). Many OATP1B1 inhibitors, such
as cyclosporine A, gemfibrozil, and ritonavir, have inhibitory effects on metabolic enzymes and/or other
transporters. Moreover, the disposition of most OATP1B1 substrates depends on additional
pharmacokinetic mechanisms such as CYP-mediated metabolism (Niemi et al. 2011). These factors
complicate the evaluation of OATP1B1 contribution in pharmacokinetics based on DDI data, and
therefore, pharmacogenetic studies provide the most reliable means to examine it, especially if the
studied drug is a sensitive OATP1B1 substrate.
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6. Clopidogrel
Clopidogrel irreversibly antagonizes ADP receptor subtype P2Y12 and subsequently inhibits the ADP-
induced activation of glycoprotein IIb–IIIa integrin complex and its binding to fibrinogen, thus preventing
platelet aggregation and thrombus formation (Gachet et al. 1990, Hollopeter et al. 2001, Schrör 1998).
Clopidogrel belongs to the same thienopyridine class as ticlopidine and prasugrel, whereas the
reversible P2Y12 inhibitor ticagrelor is a cyclopentyl-triazolopyrimidine derivative (Angiolillo et al. 2017).
The molecular weight of clopidogrel base is 321.8 g/mol (FDA 2010).
Due to the good efficacy and tolerable safety profile, clopidogrel is widely used in acute care and
secondary prevention of strokes and myocardial infarction, and in peripheral artery disease (EMA 2008,
FDA 2010). In one study of 19,185 patients, clopidogrel demonstrated a marginal benefit in reducing
the risk of a composite outcome cluster of ischemic stroke, myocardial infarction, or vascular death,
when compared to aspirin (CAPRIE Steering Committee 1996). This finding has not been replicated, but
the clopidogrel-aspirin combination has exhibited additional efficacy contrasted with aspirin
monotherapy (FDA 2010). Owing to its pharmacodynamic action, bleeding is the most prominent
adverse event caused by clopidogrel. Moreover, rash, nausea, constipation, and pruritus have been
associated with clopidogrel use.
6.1. Pharmacokinetics
At least 50% of orally administered clopidogrel is absorbed, based on urinary elimination of clopidogrel
metabolites (FDA 2010). The parent clopidogrel is inactive, and two distinct routes dominate its
extensive metabolism. The predominant pathway is the CES1-mediated hydrolysis to inactive carboxylic
acid metabolite, which is subsequently glucuronidated to acyl-?-D-glucuronide by several UGT2B
isoenzymes, namely UGT2B7, UGT2B17, and UGT2B4 (about 85–90% of the absorbed dose) (Ji et al.
2018, Kahma et al. 2018, Tang et al. 2006, Tarkiainen et al. 2015). CES1 is mainly expressed in the
endoplasmic reticulum of hepatocytes (Satoh and Hosokawa 2006). The CES1 c.428G>A (p.Gly143Glu,
rs71647871), a single nucleotide variation leading to decreased enzyme function, impairs clopidogrel
hydrolysis and increases its antiplatelet efficacy (Tarkiainen et al. 2015). The minor metabolism route is
the two-step bioactivation by CYP enzymes, which involves less than 10% of the ingested dose (Figure
1) (Farid et al. 2010). Based on in vitro data, the intermediate in clopidogrel bioactivation, 2-oxo-
clopidogrel, is formed by CYP1A2, CYP2C19, and CYP2B6, whereas the formation of the active cis-5-thiol
metabolite is mediated by CYP2B6, CYP2C19, and CYP3A4 (Kazui et al. 2010). In 2011, Bouman and
colleagues suggested a significant role for paraoxonase 1 in clopidogrel bioactivation (Bouman et al.
2011), but other studies, including a meta-analysis that combined results from 13 reports, have failed
to support this hypothesis (Mega et al. 2016). Contemporarily, CYP2C19 and CYP3A4 are considered to
be the essential enzymes in clopidogrel bioactivation in vivo.
Clopidogrel exhibits nonlinear metabolite kinetics: raising the dose from 75 mg to 300 mg results in 2.7-
fold increase in the AUC of clopidogrel active metabolite (Bristol-Myers Squibb/ Sanofi Pharmaceuticals
2018). Clopidogrel bioactivation is a very rapid process and both the 2-oxo-intermediate and the active
metabolite are extremely unstable, which has posed analytical challenges in determining their exposure.
In 2010, a publication presented a derivatization method for stabilizing the active cis-5-thiol metabolite
(Delavenne et al. 2010), which facilitated the reliable quantification of active metabolite exposure,
whereas the determination of 2-oxo-clopidogrel has been unsuccessful in vivo. The platelet aggregation
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inhibition by clopidogrel can be measured with several methods, but the most commonly applied
system (VerifyNow P2Y12; Accumetrics, San Diego, USA) is based on a turbidimetric optical detection
(Jeong et al. 2012, Lordkipanidze et al. 2008). Furthermore, the antiplatelet effect of clopidogrel
measured with VerifyNow P2Y12 system correlates well with its therapeutic efficacy (Price et al. 2008).
Carriers of loss-of-function CYP2C19 alleles have exhibited an impaired clopidogrel antiplatelet response
that has led the manufacturer to alert healthcare providers about diminished antithrombotic effect in
poor CYP2C19 metabolizers (Bristol-Myers Squibb/ Sanofi Pharmaceuticals 2018, Simon et al. 2009).
The association between CYP2C19 loss-of-function alleles and diminished clinical efficacy of clopidogrel
has been reasonably well-documented, but the benefits of genotyping-based antiplatelet therapy has
been questioned by a systematic review of 11 overlapping meta-analyses (Osnabrugge et al. 2015).
Although most included meta-analyses reported significant associations between diminished clinical
efficacy and CYP2C19 loss-of-function alleles, between-study heterogeneity and publication bias were
handled differently the across meta-analyses. Therefore, the meta-analyses drew partly discordant
conclusions concerning the advantages of antiplatelet therapy based on CYP2C19 genotype
(Osnabrugge et al. 2015). In contrast to carriers of CYP2C19 loss-of-function alleles, those of the
CYP3A4*22 or CYP3A4*5 alleles have not demonstrated diminished clopidogrel bioactivation (Holmberg
et al. 2019).
6.2. Drug-drug interactions
Consistent with the impact of CYP2C19 genotype on clopidogrel response, the CYP2C19 inhibitor
omeprazole has decreased clopidogrel bioactivation in humans (Gilard et al. 2008). Furthermore, the
CYP1A2, CYP2C19, and CYP2D6 inhibitor fluvoxamine has impaired clopidogrel’s platelet aggregation
inhibition, with the most relevant mechanism being interpreted as CYP2C19 inhibition (Hirsh-Rokach et
al. 2015). In addition, grapefruit juice, which contains furanocoumarins that act as mechanism-based
inhibitors of intestinal CYP3A4 (Edwards et al. 1996, Fukuda et al. 1997, Schmiedlin-Ren et al. 1997), has
markedly decreased the exposure and platelet inhibition of clopidogrel active metabolite (Holmberg et
al. 2014). The CYP3A4 inhibitor ketoconazole has attenuated the antiplatelet effect of clopidogrel active
metabolite and decreased its AUC and Cmax to 71–78% and to 39–52%, respectively (Farid et al. 2007).
Decreased clopidogrel response has been observed in individual HIV patients on ritonavir-containing
antiretroviral therapy (Marsousi et al. 2018, Metzger and Momary 2014), but sufficient systematic
pharmacokinetic data have been lacking.
In addition to the aforementioned CYP2C8 MBI, clopidogrel causes pharmacokinetic DDIs also via other
mechanisms. In vitro studies have reported that parent clopidogrel inhibits CYP2C19 and acts as a
mechanism-based inhibitor of CYP2B6 (Nishiya et al. 2009, Richter et al. 2004). In humans, clopidogrel
has inhibited the CYP2B6-mediated hydroxylation of bupropion (indicated by a 68% decrease in
hydroxybupropion-bupropion AUC ratio), which corroborates the clinical relevance of its CYP2B6
inhibition (Turpeinen et al. 2005). As clopidogrel decreases the activity of CYP2B6 that is involved in its
own bioactivation, its pharmacokinetics are possibly less prone to changes by CYP2B6-mediated DDIs or
CYP2B6 loss-of-function genotypes. Furthermore, clopidogrel has decreased the 5-hydroxyomeprazole-
omeprazole AUC ratio (that reflects the CYP2C19-mediated metabolism of omeprazole) by 29%, which
implies that the CYP2C19 inhibitory properties of clopidogrel seem to be of small clinical relevance
(Turpeinen et al. 2005).
24
7. Other perpetrator drugs investigated with clopidogrel
7.1. Prasugrel
Similar to clopidogrel, prasugrel is an irreversible ADP-receptor subtype P2Y12 antagonist of
thienopyridine class, and it is indicated for the reduction of thrombotic cardiovascular events in patients
that have experienced an acute coronary event (FDA 2013). Compared to clopidogrel, prasugrel has
demonstrated superior efficacy in preventing cardiovascular complications, but its impact on overall
mortality has been similar with a higher rate of bleeding events (Wiviott et al. 2007). After oral
administration, CES2 completely hydrolyzes prasugrel to an inactive intermediate species, R-95913,
which then undergoes biotransformation to the active metabolite, R-138727, by CYP3A4, CYP2B6,
CYP2C19, and CYP2C9 (Farid et al. 2007, Rehmel et al. 2006). However, the CYP inducer rifampicin and
the CYP3A4 inhibitors ritonavir, ketoconazole, and grapefruit juice furanocoumarins have only a
negligible to modest impact on the exposure and/or antiplatelet effect of R-138727 (Ancrenaz et al.
2013, Farid et al. 2007, Farid et al. 2009, Holmberg et al. 2015, Marsousi et al. 2018). Moreover, studies
have not found an association between CYP2C19 or CYP2B6 loss-of-function alleles or the CYP3A4*22
allele, and diminished antiplatelet efficacy of prasugrel (Holmberg et al. 2019, Mega et al. 2009). In the
premarketing studies, the potential of prasugrel inhibit CYP2C8 was not examined in vivo, as opposed
to most other CYP-mediated DDI mechanisms (EMA 2009). As the predictable antithrombotic effect and
low DDI liability of prasugrel has made it a possible alternative to clopidogrel in certain patient
populations that are often at risk for polypharmacy, the CYP2C8 inhibition potential of prasugrel
requires clarification.
7.2. Ritonavir
Ritonavir was one of the first HIV protease inhibitors brought to market, but its antiviral doses caused a
high rate of dose-dependent adverse reactions, such as hypertriglyceridemia (AbbVie 2018). The
pharmacokinetic profile of ritonavir is highly complex as it alters the activity of several enzymes and
transporters. Ritonavir is metabolized by CYP3A4, and to a lesser extent by CYP2D6 (Hsu et al. 1998). It
acts as a potent mechanism-based inhibitor of CYP3A while weakly inducing CYP3A in continuous
administration, the net effect being inhibition (Koudriakova et al. 1998). Moreover, ritonavir causes up
to 2-fold increase in the exposure of CYP2D6 substrates, but no dosage adjustment of the victim drug
metabolized by CYP2D6 is usually required when ritonavir is applied in low doses (Aarnoutse et al. 2005,
AbbVie 2018). Owing to its strong CYP3A4 inhibitory effect, contemporary antiviral combinations apply
ritonavir as a pharmacokinetic enhancer that permits consistent effects and hence standardized dosing
of other antiviral drugs (Rathbun and Rossi 2002). Furthermore, ritonavir alters the activity of the efflux
transporter P-gp by causing a mixed inhibition-induction effect, the net result being inhibition (Kharasch
et al. 2008, Kirby et al. 2012). Accordingly, ritonavir has increased the AUC of P-gp substrates digoxin
and fexofenadin (Kharasch et al. 2008, Kirby et al. 2012), whereas it has demonstrated negligible to
slightly diminishing effect on the exposure of dabigatran (which is the active metabolite of P-gp
substrate dabigatran etexilate) (Kakadiya et al. 2018, Kumar et al. 2017). Furthermore, ritonavir has
induced the metabolism of several substrates of CYP1A2, CYP2B6, CYP2C9, CYP2C19, and UGTs (Foisy
et al. 2008). The most notable enzyme induction mechanism of ritonavir is PXR activation (Gupta et al.
2008), while a weak AhR activation has also been observed (Frotschl et al. 1998). As discussed in section
6.3., two individual reports have observed diminished clopidogrel response in HIV patients using
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antiviral medications. Therefore, the possibility of ritonavir-clopidogrel interaction supports the pursuit
of a prospective clinical DDI study.
7.3. Gemfibrozil
The fibric acid derivative gemfibrozil modifies plasma lipid concentrations primarily by activating the
PPAR-? (Backes et al. 2007). Gemfibrozil decreases serum triglycerides and increases high-density
lipoprotein levels while having a varying effect on low-density lipoproteins (FDA 2016), but it only has a
mediocre impact on cardiovascular mortality (Backes et al. 2007). Gemfibrozil is subject to extensive
oxidative metabolism and glucuronidation, and in vitro studies imply that its primary glucuronide
metabolite, gemfibrozil 1-O-?-D-glucuronide, is formed mainly by UGT2B7 (Mano et al. 2007). The
concomitant use of gemfibrozil has been associated with greatly increased risk for the CYP2C8 and
OATP1B1 substrate cerivastatin-induced rhabdomyolysis (Farmer 2001, Jones and Davidson 2005), and
gemfibrozil was found to increase cerivastatin exposure 5.6-fold (Backman et al. 2002). This DDI
remained long unrecognized, as the actual perpetrator, gemfibrozil 1-O-?-D-glucuronide, was identified
as mechanism-based inhibitor of CYP2C8 five years after the market withdrawal of cerivastatin (Ogilvie
et al. 2006). In clinical doses, gemfibrozil causes more than 98% inhibition of CYP2C8, as demonstrated
by its pronounced effect on the pharmacokinetics of the CYP2C8 index substrate repaglinide, for
example (Table 10) (Backman et al. 2009, Honkalammi et al. 2012, Niemi et al. 2003). Therefore,
regulatory authorities recommend it as a CYP2C8 index inhibitor for clinical DDI studies (EMA 2012, FDA
2017a). In addition, both the parent gemfibrozil and its glucuronide metabolite inhibit certain
membrane transporters in vitro, most notably OATP1B1, but also OATP1B3, OATP2B1, OAT3, and
sodium/taurocholate cotransporting polypeptide (NTCP) (Tornio et al. 2017). The OATP1B1 inhibition
has been considered to be a clinically relevant DDI mechanism of gemfibrozil, which also limits the
applicability of gemfibrozil as a CYP2C8 index inhibitor. Furthermore, gemfibrozil has inhibited UGT1A1
and UGT1A3 in vitro (Gan et al. 2010), but these results have not been confirmed in vivo. It is worth
noting that the sales and use of gemfibrozil have declined due to its modest clinical efficacy, in addition
to its hazardous transporter- and CYP2C8-mediated DDIs, especially with statins (Graham et al. 2004).
8. Studied victim drugs
8.1. Simvastatin
Simvastatin is a HMG-CoA reductase inhibitor that is applied widely in the primary and secondary
prevention of cardiovascular diseases (Merck 2018). In general, simvastatin is well-tolerated, but its
most conspicuous adverse effects include myopathies and hepatic transaminase elevations. While the
therapeutic daily dose of simvastatin ranges from 10 to 40 mg, premarketing trials observed that it
exhibits linear pharmacokinetics with doses as high as 120 mg. Simvastatin is administered in inactive
lactone form, which is subject to reversible nonenzymatic and CES-mediated bioactivation to
simvastatin acid (Vickers et al. 1990a, Vickers et al. 1990b). Furthermore, in vitro studies suggest that
CYP2C8 has a minor contribution in simvastatin acid formation (Prueksaritanont et al. 2003), but the
clinical relevance of CYP2C8 in simvastatin pharmacokinetics is unconfirmed. The metabolism of
simvastatin acid and the formation of other metabolites from simvastatin lactone are mainly mediated
by CYP3A4 in vitro (Prueksaritanont et al. 1997, Prueksaritanont et al. 2003). In clinical studies, the
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CYP3A4 inhibitor itraconazole has increased the AUC of simvastatin lactone and acid more than 10-fold
(Neuvonen et al. 1998), and grapefruit juice has augmented those 16- and 6.8-fold, respectively (Lilja et
al. 1998). Furthermore, ritonavir augmented simvastatin acid exposure 32-fold, when given in
combination with another CYP3A4-inhibiting protease inhibitor, saquinavir (Fichtenbaum et al. 2002).
The concomitant administration of the CYP3A4 inductor rifampicin caused 87% and 93% decreases in
the AUCs of simvastatin lactone and acid, respectively (Kyrklund et al. 2000).
Unlike parent simvastatin, simvastatin acid is highly susceptible to alterations in OATP1B1 function and
accordingly, it is one of the most sensitive of known OATP1B1 substrates (Niemi et al. 2011). A
pharmacogenetic study in 32 healthy volunteers reported that the average exposure of simvastatin acid
was 220% higher in individuals homozygous for the SLCO1B1 c.521T>C variant, when compared to those
carrying the c.521TT genotype (Pasanen et al. 2006). In a genome-wide association study (GWAS) with
patients using simvastatin 80 mg q.d., individuals exhibiting the c.521CC genotype were observed to
have an increased risk for simvastatin-induced myopathy with an odds ratio (OR) of 16.9, when
compared with c.521TT carriers (Link et al. 2008). Therefore, high-dose simvastatin treatment is not
recommended for individuals with c.521CC genotype (Ramsey et al. 2014). Furthermore, cyclosporine,
an inhibitor of CYP3A4 and several membrane transporters including OATP1B1, has increased the
simvastatin acid exposure 6–8-fold (Neuvonen et al. 2006). In addition, gemfibrozil caused a 2.9-fold
increase in simvastatin acid exposure, which demonstrated the clinical relevance of OATP1B1-mediated
hepatic uptake in simvastatin acid disposition as gemfibrozil does not inhibit CYP3A4 (Backman et al.
2000). However, the CYP2C8 inhibitory role of gemfibrozil could have been contributing to this DDI to a
minor extent. For these reasons, simvastatin is commonly applied as an index substrate for investigating
whether a perpetrator compound is a clinically relevant inhibitor of CYP3A and/or OATP1B1.
8.2. Pioglitazone
Thiazolidinedione pioglitazone is a glucose-lowering drug that mediates its effect by activating the PPAR-
? and thereby improves insulin sensitivity and inhibits gluconeogenesis (Waugh et al. 2006). When
applied in secondary prevention, pioglitazone lowers the risk of recurrent major cardiovascular events;
however, it has no beneficial effect on overall mortality (de Jong et al. 2017). Dose-related fluid
retention is a common adverse effect of pioglitazone, which can lead to exacerbation of congestive
heart failure. Pioglitazone promotes lipid storage and increases body weight, while redistributing body
fat from visceral to subcutaneous deposits. It has an oral availability of approximately 80% and presents
linear pharmacokinetics in the 2 to 60 mg dose range (Eckland and Danhof 2000). Pioglitazone
undergoes extensive biotransformation to active and inactive metabolites by CYP2C8 and to a minor
extent by CYP3A4 in vitro and in vivo (Figure 2) (Eckland and Danhof 2000, Jaakkola et al. 2005, Jaakkola
et al. 2006a). The main metabolites, primary hydroxypioglitazone (M-IV), and its secondary metabolite,
ketopioglitazone (M-III), are active and contribute to the therapeutic effect (Eckland and Danhof 2000).
Moreover, CYP2C8 has been indicated to have a dominant role in the oxidation of M-IV to M-III (Jaakkola
et al. 2005). SLCO1B1 c.521T>C genotype has not affected pioglitazone pharmacokinetics, which implies
a small to nonexistent role for OATP1B1 in its disposition (Kalliokoski et al. 2008). Furthermore,
pioglitazone has not been reported to impact CYP or transporter activity suggesting a low potential to
act as a DDI perpetrator (Eckland and Danhof 2000, Gillies and Dunn 2000).
Gemfibrozil has raised pioglitazone exposure over 3-fold (Deng et al. 2005, Jaakkola et al. 2005), and
interestingly one study reported that the mean increase was over 5-fold in CYP2C8*3 carriers, when
that was only 3.3-fold in CYP2C8*1 homozygotes (Aquilante et al. 2013). Other studies have also
associated higher pioglitazone clearance with carrying the CYP2C8*3 allele (Kadam et al. 2013, Tornio
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et al. 2008). These findings strongly imply that carrying the CYP2C8*3 allele increases the fmCYP2C8 of
pioglitazone. Owing to the increased risk for concentration-dependent adverse effects, the regulatory
authorities have recommended caution when combining gemfibrozil with pioglitazone (EMA 2010). In
contrast, itraconazole has not significantly altered pioglitazone disposition in humans indicating that
CYP3A4 has a negligible contribution in its metabolism in vivo (Jaakkola et al. 2005). Using pioglitazone
as a CYP2C8 probe substrate is supported by the dominant role of CYP2C8 in its metabolism, and by its
good tolerability in single doses.
Figure 2. Biotransformation pathways of pioglitazone, and the chemical structures of pioglitazone, and
its M-IV, M-III, and M-II metabolites. CYP, cytochrome P450.
8.3. Montelukast
Montelukast is a potent and selective cysteinyl leukotriene receptor 1 antagonist that inhibits mucus
hypersecretion and smooth muscle contraction in the bronchi, thereby providing therapeutic efficacy
in the treatment of asthma (Lipworth 1999, Reiss et al. 1998). Montelukast has an oral bioavailability of
approximately 60–70%, exhibits linear pharmacokinetics in therapeutic doses, and is approximately
99.8% bound to plasma proteins (Cheng et al. 1996, FDA 1998). Montelukast is tolerated relatively well,
however, increased incidence of neuropsychiatric symptoms, headache, and GI problems have been
reported (Benard et al. 2017, Haarman et al. 2017, Lipworth 1999). The major route in the extensive
metabolism of montelukast is the formation of its 36-hydroxy metabolite (M6) and further oxidation to
dicarboxylic acid metabolite (M4) by CYP2C8 (Figure 3) (Balani et al. 1997, Cheng et al. 1996, FDA 1998,
Filppula et al. 2011, Karonen et al. 2010). Furthermore, minor montelukast metabolites include the acyl
glucuronide (M1) formed by UGT1A3 (Cardoso Jde et al. 2015, Hirvensalo et al. 2018), and the 21-
hydroxy metabolite (M5) formed by CYP3A4 (Chiba et al. 1997, Karonen et al. 2012).
Two individual papers (a clinical DDI study and a paper incorporating data from PBPK simulations, in
vitro investigations, and in vivo experiments in rats and cynomolgus monkeys) have suggested a role for
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OATP1B1 in montelukast disposition (Hegazy et al. 2012, Varma et al. 2017). The clinical study found
that clarithromycin increased the AUC of montelukast 2.4-fold, whereas fluconazole decreased it by
31% (Hegazy et al. 2012). The authors attributed both observed DDIs to transporter-mediated
mechanisms but offered no mechanistic explanation that would fit the known DDI characteristics of
fluconazole or clarithromycin, and montelukast. In the second study, single-dose rifampicin reduced the
cellular uptake of montelukast into human hepatocytes, whereas inconsistently, another potent
OATP1B1 inhibitor, cyclosporine A, significantly increased its uptake (Varma et al. 2017). Moreover, in
human embryonic kidney (HEK) 293 cells transfected with individual human transporters, the uptake
fold-ratio of montelukast to negative (propranolol) and positive (rosuvastatin) controls were 1.4–1.9
and 0.08–0.1 (for OATP1B1), and 1.1–1.3 and 0.28–0.36 (for OATP1B3), respectively, and the
montelukast to rosuvastatin uptake fold-ratio was 0.05–0.09 (for OATP2B1), depending on the
concentration and the incubation time of montelukast. Furthermore, single-dose rifampicin decreased
montelukast clearance in rats and monkeys, but the corresponding alterations in the disposition of
pitavastatin, the prototypical OATP1B1 substrate, were markedly more pronounced (Varma et al. 2017).
A GWAS associated the UGT1A3*2 variant allele (that leads to augmented UGT1A3 expression) with
amplified montelukast clearance and increased exposure of its M1 metabolite, but it found no evidence
indicating that montelukast is a sensitive OATP1B1 substrate (Hirvensalo et al. 2018). To summarize, the
role of OATP1B1 in montelukast disposition is not fully established, but it is mediocre at best. In addition,
the common missense variants of SLCO1B3 or SLCO2B1 genes, which encode OATP1B1 and OATP2B1,
respectively, have not been associated with altered pharmacokinetics of parent montelukast
(Hirvensalo et al. 2018, Tapaninen et al. 2013).
Figure 3. Biotransformation pathways of montelukast and the chemical structures of montelukast and
its metabolites M6, M4, M5, and M1. CYP, cytochrome P450; UGT, uridine 5’-diphospho-
glucuronosyltransferase.
Early in vitro papers identified montelukast as a CYP2C8 inhibitor, but in clinical studies, it failed to affect
the pharmacokinetics of the CYP2C8 substrates pioglitazone, repaglinide, and rosiglitazone (Jaakkola et
al. 2006c, Kajosaari et al. 2006, Kim et al. 2007). Further in vitro experiments performed with
physiologically relevant free drug concentrations explained the low CYP2C8 inhibitory effect by
montelukast with its low fu in human plasma (Filppula et al. 2011). However, X-ray crystallography has
demonstrated that CYP2C8 heme interacts with the montelukast benzyl ring near the site of oxidation
in the biotransformation of montelukast to its M6, M4, and M3 metabolites (Chiba et al. 1997, Filppula
et al. 2011, Schoch et al. 2008). The observed ligand-protein interaction of montelukast and CYP2C8
prompted research into the role of CYP2C8 in montelukast metabolism. The clinical studies found that
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gemfibrozil increases montelukast AUC 4.3–4.5-fold, whereas itraconazole has only a negligible effect
on it (Karonen et al. 2010, Karonen et al. 2012). The CYP2C8-inhibitory effect of gemfibrozil primarily
accounted for the augmented montelukast exposure, thus making montelukast a potential CYP2C8
index substrate for DDI studies.
8.4. Dasabuvir
Dasabuvir inhibits nonstructural protein 5B, an RNA polymerase of HCV, and thereby disrupts the
replication of viral RNA (FDA 2014a).  Dasabuvir is routinely used in the treatment of HCV 1 infection in
conjunction with three other drugs in 3D regimen: paritaprevir, ombitasvir, and ritonavir (Deeks 2015).
Depending on the patient population, a sustained virological response has been achieved with rates of
90–100% by a twelve-week treatment with 3D regimen, but its use is currently limited by its high cost
(Klibanov et al. 2015). The adverse effects of the 3D combination include pruritus, skin reactions,
insomnia, and elevated serum alanine aminotransferase levels. Dasabuvir has an oral bioavailability of
about 70% and is more than 99.9% bound to plasma proteins. It exhibits linear pharmacokinetics in
clinically relevant dose ranges and has a mean terminal t½ of about 7 hours (King et al. 2017). In vitro
and in silico, CYP2C8 metabolizes 60% of dasabuvir to the primary tert-butyl hydroxyl metabolite (M1),
the most abundant metabolite in human plasma, whereas CYP3A4 contribution in dasabuvir
biotransformation is about 30% (King et al. 2017, Shebley et al. 2017b, Shen et al. 2016). Based on
clinical data, the role of CYP2C8 in dasabuvir metabolism seems to be more pronounced in vivo than in
vitro, and conversely, that of CYP3A4 appears to be of lesser importance (Menon et al. 2015). In
addition, dasabuvir has been suggested to be a substrate of P-gp and BCRP, and the 3D regimen has
been observed to inhibit UGT1A1 and BCRP.
Most clinical research that focused on characterizing the pharmacokinetics and DDI potential of
dasabuvir has been performed with concurrently administered paritaprevir, ombitasvir, and ritonavir.
This has complicated the data interpretation and has required examination of the individual
pharmacokinetic characteristics of dasabuvir. When given concurrently with ritonavir, gemfibrozil has
increased the Cmax and AUC of dasabuvir 2.0- and 11.3-fold, respectively, while prolonging its t½ from 5
to 90 hours (Menon et al. 2015). The CYP3A4 and P-gp inhibitor ketoconazole has caused only a modest
1.4-fold increase in the AUC of dasabuvir with an insignificant effect on the Cmax. Furthermore, the CYP
inducer carbamazepine has decreased dasabuvir Cmax and AUC to 45% and 30%, respectively. For these
reasons, studies have concluded that concomitant use of dasabuvir and potent CYP2C8 inducers or
inhibitors is contraindicated (FDA 2014a). The dominant role of CYP2C8 in dasabuvir metabolism has
raised questions concerning the safety of coadministered clopidogrel and dasabuvir; however, a PBPK
study suggested only a “limited” DDI between the two drugs (Shebley et al. 2017a, Stark 2015). As
supratherapeutic dasabuvir exposure is associated with decreased hemoglobin levels and potential to
prolong the QTc interval (FDA 2014b), additional clinical examinations with other CYP2C8 inhibitors and
dasabuvir were urged (Stark 2015).
8.5. Desloratadine
Desloratadine is a nonsedating histamine 1 receptor inverse agonist indicated for the symptomatic
treatment of allergic rhinitis and urticaria (FDA 2014c, Henz 2001). It exhibits linear pharmacokinetics
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in the therapeutic dose range and is extensively metabolized (Henz 2001, Molimard et al. 2004,
Murdoch et al. 2003). The safety profile of desloratadine resembles that of placebo, albeit pharyngitis,
dry mouth, and fatigue have been 1–2% more common in allergic rhinitis patients using desloratadine.
In normal doses, desloratadine has not significantly altered the QTc interval (FDA 2014c, Henz 2001),
and its dosages exceeding nine times the normal therapeutic upper limit have prolonged QTc by 8.1 and
0.4 ms, when Bazett and Friedricia corrections were applied, respectively (FDA 2014c). CYP3A4, CYP2D6,
and CYP2C19 convert desloratadine to its minor 5-hydroxy and 6-hydroxy metabolites, but the
enzymatic mechanism responsible for the formation of the major 3-hydroxy metabolite was long
unclear (Barecki et al. 2001). In 2015, an in vitro study observed that CYP2C8 could form 3-
hydroxydesloratadine, but only if coincubated with UGT2B10 (Figure 4) (Kazmi et al. 2015).
Figure 4. The proposed biotransformation pathways and the chemical structures of desloratadine and
its 5-hydroxy, 6-hydroxy, N-glucuronide, 3-hydroxy, and 3-hydroxy-O-glucuronide metabolites (Kazmi et
al. 2015). CYP, cytochrome P450; UGT, uridine 5’-diphospho-glucuronosyltransferase.
Accordingly, four distinct steps were proposed for the dominant metabolism route of desloratadine.
First, UGT2B10 forms an N-glucuronide, which then undergoes a rapid CYP2C8-mediated 3-
hydroxylation (Kazmi et al. 2015). Subsequently, the produced 3-hydroxy metabolite is further
glucuronidated to 3-hydroxydesloratadine-O-glucuronide by UGT1A1, UGT1A3, and UGT2B15, which
was reported soon after desloratadine marketing approval (Ghosal et al. 2004). Kazmi and colleagues
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were unable to detect desloratadine-N-glucuronide in their experiments, however, which was explained
by its hypothetically unstable nature (Kazmi et al. 2015). A subset of the general population (ranging
from 2% in Caucasians and Hispanics to 17% in African Americans) has a decreased capacity to form 3-
hydroxydesloratadine. These individuals are described as desloratadine “poor metabolizers”, whose
desloratadine exposure and 3-hydroxydesloratadine:desloratadine AUC ratio are 600% and 21% of
those of “normal desloratadine metabolizers”, respectively (FDA 2014c, Prenner et al. 2006).
Furthermore, membrane transporters have not been observed to participate in desloratadine
disposition to a clinically relevant extent (Henz 2001, Murdoch et al. 2003). In addition, desloratadine
has not exhibited significant effects on CYP enzyme or drug transporter activity. In clinical DDI studies,
ketoconazole has augmented desloratadine exposure 1.4-fold, whereas azithromycin, grapefruit juice,
erythromycin, fluoxetine, and cimetidine have caused a smaller to nonexistent alterations desloratadine
pharmacokinetics. To summarize, the proposed 3-hydroxylation mechanism of desloratadine could
make it a potential CYP2C8 index substrate, but this question requires addressing with clinical data.
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AIMS OF THE WORK
The ADP-receptor subtype P2Y12 antagonist clopidogrel markedly increases the exposure of repaglinide,
which is a CYP2C8, OATP1B1, and CYP3A4 substrate. However, the interaction profile of clopidogrel has
not been characterized in detail. In addition, specific, safe, and sensitive CYP2C8 index substrates are
lacking, although they are highly warranted for DDI studies. Clopidogrel is a prodrug bioactivated partly
by CYP3A4, but the effect of CYP3A4 inhibitors on its pharmacokinetics, such as ritonavir, has remained
partly unexplored. This work primarily aimed to examine the potential of clopidogrel to alter the
pharmacokinetics of different CYP2C8, OATP1B1, and CYP3A4 substrates, and to screen clinically
relevant pharmacokinetic interactions by clopidogrel. Moreover, the target was to search for potential
CYP2C8 index substrates to be utilized in DDI studies.
Specific aims of individual studies:
Study I To investigate the effect of clopidogrel in loading and maintenance doses on the
pharmacokinetics of simvastatin, a sensitive CYP3A4 and OATP1B1 substrate.
Study II To examine whether clopidogrel alters the pharmacokinetics of the CYP2C8 substrate
pioglitazone.
Study III To characterize the effects of clopidogrel and prasugrel on the pharmacokinetics of
montelukast, a CYP2C8 substrate.
Study IV To explore the impact of clopidogrel on the pharmacokinetics of the CYP2C8 substrate
dasabuvir with or without concurrently administered CYP3A4 inhibitor ritonavir.
Secondarily, the aim was to examine the ability of ritonavir to modify clopidogrel
bioactivation.
Study V To investigate whether clopidogrel and the strong CYP2C8 inhibitor gemfibrozil affect the
pharmacokinetics of desloratadine, a proposed CYP2C8 substrate.
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MATERIALS AND METHODS
1. Subjects
Twelve healthy Finnish volunteers took part in each study, except for Study II, in which ten subjects
participated (Table 1). One subject withdrew from Study V due to personal reasons, but all other
participants completed the studies. One male subject participated in two studies (Studies II and IV)
totaling 56 subjects (27 female, 29 male). In each study, the number of participants was estimated to
be sufficient to detect at least a 30% difference in the AUC of investigated drugs between phases or
groups, with a power of 80% (?-level 5%). The subjects’ health was confirmed by medical history, clinical
examination, the following routine laboratory tests, and electrocardiography (only in Study IV) before
entering the studies. All subjects had normal blood pressure, glomerular filtration rate, plasma sodium
and potassium levels, blood thrombocyte counts, and hemoglobin values. Only clinically insignificant
divergences were approved in plasma alanine aminotransferase, alkaline phosphatase, gamma-glutamyl
transferase, and creatine kinase (only in Study I) levels. Before participation, plasma human chorionic
gonadotropin was measured from every female participant to exclude pregnancy. None of the subjects
used continuous medication, hormonal contraception, or tobacco products. Use of other drugs or
omega-3 fatty acid dietary supplements were not permitted from 1 week before to 1 week after each
study. Furthermore, consumption of grapefruit-derived products was not allowed one week before and
during the studies. Strenuous exercise and use of alcohol were prohibited the day before, and on the
days when the victim drugs were administered. Participating in other trials or donating blood within
three months before and after each study was also prohibited.
Table 1. Characteristics of participants
Study number (n) Sex (f/m) Age (years) BMI (kg/m2)
I (12) 4/8 22; 19–27 22.7; 18.6–25.9
II (10) 4/6 26; 20–35 22.4; 19.2–28.9
III (12) 7/5 25; 19–31 24.6; 20.2–26.8–(33.0*)
IV (12) 6/6 25; 20–33 22.4; 19.4–26.6
V (11) 6/5 23; 20–29 23.1; 18.7–27.3
Age and body mass index (BMI) data are presented as arithmetic mean with range; f, females; m, males.
In Study III, one subject (indicated with *) had a BMI of 33.0 due to athletic body composition.
2. Study Design
These placebo-controlled pharmacokinetic studies with clopidogrel and possible additional drugs as
perpetrator pretreatments (prasugrel, ritonavir, and gemfibrozil in Studies III, IV, and V, respectively)
were carried out with a randomized crossover design. The victim drugs were simvastatin, pioglitazone,
montelukast, dasabuvir and clopidogrel, and desloratadine in Studies I, II, III, IV, and V, respectively
(Tables 2, 3, 4, 5, and 6).  Ritonavir and gemfibrozil pretreatments were partly performed by the subjects
at home, unsupervised, but the volunteers were instructed to be punctual with the dosing schedule and
document the time when gemfibrozil or ritonavir were ingested. On the actual study days, the victim
drugs were administered one hour after the pretreatment to allow dissolution and disintegration of
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perpetrator tablets. All drugs were ingested with 150 ml of water, and depending on the study, the
subjects spent the following 9–12 hours under medically supervised conditions. Standardized warm
meals were served 3 hours, and snacks 7 hours, and 9 hours (Study IV) or 10 hours (Studies I–III and V)
after the administration of the victim drugs. Depending on the pharmacokinetic profiles of the
administered drugs, study phases were separated by a wash-out period of 2–3 weeks in each study.
Table 2. Design of Study I
Pretreatment phase Day 1
8 AM 9 AM
Placebo Placebo Simvastatin
40 mg
Clopidogrel 300 mg Clopidogrel
300 mg
Simvastatin
40 mg
Clopidogrel 75 mg Clopidogrel
75 mg
Simvastatin
40 mg
Table 3. Design of Study II
Pretreatment
phase
Day 1 Days 2 and 3
8 AM 9 AM 8 AM
Placebo Placebo Pioglitazone
15 mg
Placebo
Clopidogrel Clopidogrel
300 mg
Pioglitazone
15 mg
Clopidogrel
75 mg
Table 4. Design of Study III
Pretreatment
phase
Day 1 Day 2
8 AM 9 AM 8 AM
Placebo Placebo Montelukast
10 mg
Placebo
Clopidogrel Clopidogrel
300 mg
Montelukast
10 mg
Clopidogrel
75 mg
Prasugrel Prasugrel
60 mg
Montelukast
10 mg
Prasugrel 60
mg
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Table 5. Design of Study IV
Pretreatment
phase
Days 1 and 2 Day 3 Days 4 and 5
8 AM 8 PM 8 AM 9 AM 8 PM 8 AM 8 PM
Placebo – – Placebo DAS
250 mg
– Placebo –
Ritonavir RIT
100 mg
RIT
100 mg
RIT
100 mg
DAS
250 mg
RIT
100 mg
RIT
100 mg
RIT
100 mg
Clopidogrel – – CLOP
300 mg
DAS
250 mg
– CLOP
75 mg
–
Clopidogrel
and ritonavir
RIT
100 mg
RIT
100 mg
CLOP
300 mg
and RIT
100 mg
DAS
250 mg
RIT
100 mg
CLOP
75 mg
and RIT
100 mg
RIT
100 mg
CLOP, clopidogrel; DAS, dasabuvir; RIT, ritonavir.
Table 6. Design of Study V
Pretreatment
phase
Days 1 and 2 Day 3 Days 4 and 5
8 AM 8 PM 8 AM 9 AM 8 PM 8 AM 8 PM
Placebo – – Placebo DES
5 mg
– Placebo –
Clopidogrel – – CLOP
300 mg
DES
5 mg
– CLOP
75 mg
–
Gemfibrozil GEM
600 mg
GEM
600 mg
GEM
600 mg
DES
5 mg
GEM
600 mg
GEM
600 mg
GEM
600 mg
CLOP, clopidogrel; DES, desloratadine; GEM, gemfibrozil.
The following drugs used in the studies were supplied by the Pharmacy of Helsinki University Central
Hospital: clopidogrel (Plavix 300 mg and 75 mg tablets; Sanofi- Aventis, Paris, France); prasugrel (Efient
10 mg tablets; Eli Lilly, Nederland BV, Houten, The Netherlands); ritonavir (Norvir 100 mg tablets;
AbbVie, Ludwigshafen am Rhein, Germany); gemfibrozil (Lopid 600 mg tablets; Pfizer Manufacturing
Deutschland GmbH, Freiburg, Germany); simvastatin (Zocor 40 mg tablets; MSD, Hoddeson, United
Kingdom); pioglitazone (Actos 15 mg tablets; Takeda Europe, London, UK), dasabuvir (Exviera 250 mg
tablets; AbbVie); desloratadine (Aerius 5 mg tablets; MSD); and placebo (Placebo tablets; University
Pharmacy, Helsinki, Finland).
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3. Sampling
For the pharmacokinetic and pharmacodynamic measurements, timed blood samples were drawn from
a cannulated forearm vein, or by venipuncture according to a predetermined schedule, which differed
from one study to another, depending on the pharmacokinetic profiles of the used drugs. In Study I,
samples were taken before the administration of pretreatment, and 5 minutes before and 0.5, 1, 1.5, 2,
2.5, 3, 4, 5, 7, 9, and 12 hours after administering simvastatin. In Study II, blood samples were drawn
before the administration of pretreatment, and 5 minutes before and 1, 2, 3, 4, 5, 7, 9, 12, 24, 48, and
72 hours after the administration of pioglitazone. In Study III, samples were taken before the
administration of pretreatment, and 5 min before and 0.5, 1, 2, 3, 4, 5, 7, 9, 12, 24, and 48 h after the
administration of montelukast. In Study IV, blood samples were drawn before the administration of
pretreatment, and 5 minutes before and 0.5, 1, 2, 3, 4, 6, 9, 23, 47, and 71 hours after the dasabuvir
ingestion. In Study V, samples were taken before pretreatment, and 5 minutes before and 0.5, 1, 2, 3,
4, 5, 7, 9, 11, 23, 47, and 71 hours after desloratadine administration. For the determination of the
clopidogrel antiplatelet effect in Study IV, anticoagulated whole-blood samples were collected in citrate
tubes at just before, and 55 minutes, 2, 4, 10, and 24 hours after clopidogrel dosing.
Blood samples were collected into EDTA-containing tubes, which were placed on ice immediately after
sampling. Plasma was separated within 30 minutes and stored at -70 ºC until analysis. The samples for
the determination of clopidogrel active metabolite, and prasugrel metabolites R-138727 and R-95913,
were treated with 2-bromo-3’-methoxyacetophenone within 30 seconds of blood sample collection in
whole blood EDTA samples for the derivatization of the active metabolite of clopidogrel and prasugrel,
as originally described by Delavenne and colleagues, and Farid and colleagues (Delavenne et al. 2010,
Farid et al. 2007).
4. Determination of drug concentrations
The lower limits (LLQ) of quantification and the day-to-day coefficients of variation (CV) of all analyzed
compounds are given in Table 7. The bioanalytical methods are described in more detail in the original
publications. The matrix used was human plasma, and no interfering peaks were observed at the mean
retention times of analytes, except in Study I (see section 7). All analyses were performed with liquid
chromatography-tandem mass spectrometry.
Table 7. Summary of bioanalytical variables in each study
Study Analyte LLQ  (ng/ml or S/N*) Day-to-day CV (%)
 I–V Clopidogrel 0.05 < 10
 I–V Clopidogrel active metabolite 0.05 < 15
 I–IV; V Clopidogrel carboxylic acid 100; 20 < 15
 I–IV; V Clopidogrel acyl-?-D-glucuronide 100; 25 < 15
 I Simvastatin 0.04 < 15
 I Simvastatin acid 0.05 < 15
 II Pioglitazone 0.2 < 15
 II Hydroxypioglitazone (M-IV) 0.5 < 15
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 II Ketopioglitazone (M-III) 0.5 < 15
III Prasugrel R-138727 metabolite 0.1 < 15
 III Prasugrel R-95913 metabolite 0.2 < 15
 III Montelukast 2.0 < 9
 III Montelukast acyl-?-D-glucuronide (M1) 0.5 < 8
 III Montelukast 1,2-diol (M6) 0.2 < 8
 III 21(S)-hydroxy montelukast (M5a) 0.25 < 6
 IV Ritonavir 5.0 < 9
 IV Dasabuvir 0.8 < 10
 IV Tert?butyl hydroxyl dasabuvir (M1) 10:1* –
 V Gemfibrozil 50 < 10
 V Gemfibrozil-1-O-glucuronide 50 < 10
 V Desloratadine 0.05 ? 6
 V 3-hydroxydesloratadine 0.025 < 5
 V 3-hydroxydesloratadine-O-glucuronide 3:1* –
The LLQ data are given as nanograms per milliliter, or as a signal-to-noise ratio (indicated with *).
5. Platelet aggregation measurements
In Study IV, the inhibition of platelet aggregation by clopidogrel was tested using the VerifyNow P2Y12
turbidimetric optical detection system (Accumetrics, San Diego, USA) (Jeong et al. 2012, Lordkipanidze
et al. 2008) within 2 hours of sampling. Whole blood samples were injected to a standard cartridge
composed of two channels. One channel contained a mixture of ADP and PGE1, the latter being included
to improve the specificity of the PRU result to reflect the antiplatelet impact of clopidogrel taking place
via P2Y12 receptor activation. The second channel contained thrombin receptor activating peptide
(TRAP) to induce platelet aggregation with no ADP receptor activation. As thrombocyte aggregation
occurred, the system converted luminosity transmittance results into arbitrary P2Y12 reaction units
(PRU) for the ADP/PGE1 channel and arbitrary BASE units for the TRAP channel. In addition to reporting
the results in arbitrary units, a platelet inhibition percentage was given. The average inhibition values
were calculated by dividing the area under the effect-time curve from time 0 to 24 hours by the
corresponding time interval.
6. Genotyping
Buffy coats were prepared from 9 ml whole-blood EDTA samples after plasma separation. Genomic DNA
was extracted from the buffy coats using the Maxwell 16 LEV Blood DNA Kit on a Maxwell 16 Research
automated nucleic acid extraction system (Promega, Madison, USA). Depending on the study,
participants were genotyped for some of the following alleles (Table 8): CYP2C8*2 (rs11572103) *3
(rs10509681 and rs11572080), and *4 (rs1058930); CYP2C19*2 (rs4244285), *3 (rs4986893), *8
(rs41291556), and *17 (rs12248560); UGT1A3*2 (rs3821242 and rs6431625), *3 (rs3821242), and *6
(rs3821242, rs6431625, and rs45449995); CES1 c.428G>A (rs71647871); and SLCO1B1 c.521T>C
(rs4149056). Genotyping was performed with commercially available or custom TaqMan assays with
38
OpenArray technology on a QuantStudio 12K Flex real-time polymerase chain reaction system (Life
Technologies, Carlsbad, USA).
Table 8. Genotypes of the study subjects
Study number (n) Genotype (n) Number of subjects
I (12) SLCO1B1 c.521TT
SLCO1B1 c.521TC
9
3
II (10) CYP2C8*1/*2
CYP2C8*1/*3
CYP2C8*1/*4
CYP2C8*1/*1
1
3
2
4
III (12) CYP2C8*1/*1
CYP2C8*1/*2
CYP2C8*1*3
UGT1A3*1/*1
UGT1A3*1/*2
UGT1A3*1/*3
UGT1A3*2/*2
UGT1A3*3/*3
CYP2C19*1/*1
CYP2C19*1/*17
CES1 c.428G/G
CES1 c.428G/A
9
1
2
1
8
1
1
1
5
7
11
1
IV (12) CYP2C8*1/*1
CYP2C8*1/*2
CYP2C8*1/*3
CYP2C8*1/*4
CYP2C19*1/*1
CYP2C19*1/*2
CYP2C19*1/*17
CYP2C19*2/*17
CES1 c.428G/G
CES1 c.428G/A
9
1
1
1
1
3
6
2
10
2
V (11) CYP2C8*1/*3
CYP2C8*1/*4
CYP2C8*1/*1
2
2
7
7. Pharmacokinetic calculations
The pharmacokinetics of all analyzed compounds were characterized by Cmax, tmax, t½, AUC0–?, and
appropriate partial AUCs. Pharmacokinetics were calculated by noncompartmental analysis using MK-
Model, version 5.0 in Study I (Biosoft, Cambridge, UK), and Phoenix WinNonlin, version 6.4 in Studies II–
V (Certara, Princeton, USA). The terminal log-linear part of each concentration-time curve was identified
visually. The ke was determined by linear regression analysis of the log-linear part of the plasma
concentration time curve. The t½ value was calculated by the equation t½ = ln 2/ke. The AUC values were
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calculated by using a combination of the linear (for increasing concentrations) and log-linear (for
decreasing concentrations) trapezoidal rules, with extrapolation to infinity, when appropriate, by
dividing the last measured concentration by ke.
When the effect of clopidogrel 75 mg on simvastatin pharmacokinetics was examined two days after
exploring the effect of the 300 mg dose in Study I, certain individuals had residual concentrations of
simvastatin and simvastatin acid from the preceding phase. These were taken into account by
subtracting the residual AUC from the observed AUC. The residual AUC was calculated by dividing the
residual concentration by the ke estimated in the preceding phase. Residual concentrations were
observed in 8 and 10 of the individuals for simvastatin and simvastatin acid, respectively. The geometric
mean residual AUC0–? of simvastatin and simvastatin acid were 2% and 4% of the total AUC0–? observed,
respectively.
8. Statistical analyses
Based on the pharmacokinetic results of previous drug interaction studies with the victim drugs, 10
(Study II) or 12 (Studies I and III-V) subjects were estimated to be adequate to detect about 30% change
in the AUC of victim drugs between the placebo and perpetrator phases, with a power of at least 80%
(? level 5%). The pharmacokinetic results were expressed as geometric means and geometric mean
ratios with geometric CV or 90% CIs, excluding tmax, which were given as median with range. In Study IV,
the results of the platelet aggregation measurements were presented as arithmetic means with
standard deviation. Logarithmic transformation was used for pharmacokinetic variables, except for tmax,
before statistical analysis. The pharmacokinetic parameters were compared by repeated-measures
analysis of variance with treatment phase as a within-subjects, and treatment sequence as a between-
subjects factor in Studies I and II, with pairwise comparisons with the Fisher’s least significant difference
method. Because Studies IV and V compared the pharmacokinetic parameters of dasabuvir and its M1
metabolite, and desloratadine and its metabolites, respectively, between all the pretreatment phases,
they applied Bonferroni correction. The tmax data were compared using the Wilcoxon signed rank test.
In Studies II–V, the correlations between the AUC0-? of clopidogrel acyl-?-D-glucuronide, and the
changes in the pharmacokinetics of the victim drugs (metabolite:parent drug AUC ratio and AUC fold-
changes) were quantified as Kendall’s (Study IV) or Pearson’s correlation coefficients and tested using
Kendall’s test (Study IV) or t-test (Studies II, III, and V). In all the studies, P-values below 0.05 were
considered significant. Statistical analyses were performed using SPSS Statistics for Windows, version
22.0 (IBM, Armonk, NY).
9. Static in vivo-in vitro predictions and physiologically-based pharmacokinetic simulations
In Studies II and V, previously published in vitro inhibitor concentrations that support half maximal rate
of inactivation, and maximal inactivation rate values of clopidogrel acyl-?-D-glucuronide for CYP2C8
were applied to predict the in vivo clopidogrel-pioglitazone, clopidogrel-desloratadine, and gemfibrozil-
desloratadine interactions with the following equation (Mayhew et al. 2000):
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where kdeg is the rate constant of hepatic P450 degradation in the absence of the inhibitor, kinact is the
maximum inactivation rate, I is the unbound inhibitor concentration at the enzyme site, and KI is the
inhibitor concentration needed to cause half of kinact. The values used were obtained from previous
studies (Backman et al. 2009, Ogilvie et al. 2006, Tornio et al. 2014).
To elucidate the mechanisms of the clopidogrel-montelukast interaction and to predict the magnitude
of the clopidogrel-montelukast DDI in steady-state caused by the clinical dosing of clopidogrel, PBPK
models were constructed in the Simcyp Population-Based Simulator version 15.1 (Simcyp, Sheffield, UK).
The montelukast and perpetrator drug models were validated by simulating previous DDI studies
available in the literature. Two clopidogrel models were refined and validated for the PBPK simulations.
The clopidogrel models differed with respect to the unbound hepatocyte-to-plasma ratio and OATP1B1
KI of clopidogrel acyl-?-D-glucuronide, which were 8 and 0.1 μM, and 25 and 5.45 μM. Thereafter, two
montelukast models were constructed: a perfusion-limited liver model, and a permeability-limited liver
model with OATP1B1 transport. In both montelukast models, CYP2C8 was the main enzyme involved in
the metabolism of montelukast. To examine the clopidogrel–montelukast interaction, the fmCYP2C8 was
varied between 0.55 and 0.80.
10. Ethical and safety considerations
The Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District, and the Finnish
Medicines Agency approved the study protocols. All participants received both oral and written
information and signed an informed consent prior to participating in the studies. All the administered
drugs are considered to possess a relatively benign safety profile with low risk for serious adverse
reactions, especially in short-term use. The potential pharmacokinetic interactions were not estimated
to markedly change the risk profile of the victim drugs when they are administered in single doses to
healthy volunteers. The only invasive procedures done to the subjects were forearm vein cannulation
and venipuncture, which pose only minimal risk for serious complications. The volunteers were under
medical supervision 10–12 hours after the victim drugs were administered, and they were given a card
that contained the names, dates, and dosages of the drugs that were administered. In case of
emergencies, two of the researchers were available via telephone around the clock during the studies.
In Study I, one subject developed a minor atraumatic hematoma in the left arm after clopidogrel
pretreatment, and in Study IV, two subjects experienced transient and spontaneously resolved nausea
after the first ritonavir dose, which did not reappear after the following doses. No other or major
adverse effects were observed.
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RESULTS
1. Effect of clopidogrel on the pharmacokinetics of simvastatin (Study I)
Figure 5. Effects of clopidogrel 300 mg and clopidogrel 75 mg on the Cmax, AUC0-12h, and t½ of simvastatin.
Bars represent geometric mean ratios to the placebo phase (%) with 90% confidence intervals.
Figure 6. Effects of clopidogrel 300 mg and clopidogrel 75 mg on the Cmax, AUC0-12h, and t½ of simvastatin
acid. Bars represent geometric mean ratios to the placebo phase (%) with 90% confidence intervals.
By clopidogrel 300 mg, the AUC0-2h of simvastatin and simvastatin acid were 156% (P = 0.02, 90% CI of
the geometric mean ratio 116–209%) and 148% (P = 0.04, 90% CI 109–201%) of those when placebo
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was coadministered. The lower clopidogrel dose did not affect the AUC0-2h of simvastatin or simvastatin
acid. No significant changes were observed in the Cmax, tmax, AUC0-12h, AUC0–?, or t½ of simvastatin or
simvastatin acid by either clopidogrel dose (Figures 5 and 6). Three of the subjects were heterozygous
for the SLCO1B1 c.521T>C SNV and none were homozygous, while other subjects carried the c.521TT
genotype.
2. Effect of clopidogrel on the pharmacokinetics of pioglitazone (Study II)
In the clopidogrel phase, the AUC0–? of pioglitazone, its primary hydroxy metabolite (M-IV) and
secondary keto metabolite (M-III) were 214% (P = 9·10-5, 90% CI of the geometric mean ratio 176–
261%), 105% (P > 0.9, 90% CI 90–122%), and 105 % (P > 0.9, 90% CI 89–124%) of those in the placebo
phase (control), respectively (Figure 7). Thereby, clopidogrel decreased the M-IV:pioglitazone AUC0-?
ratio, an index of the CYP2C8-mediated clearance of pioglitazone, to 49% (P = 0.0001, 90% CI 40–59%)
of that when placebo was coadministered. The pioglitazone Cmax remained unchanged, whereas the Cmax
of M-IV and M-III were 61% (P = 0.007, 90% CI 48–79%) and 58% (P = 0.003, 90% CI 46–74%) of control,
respectively. The C24 of pioglitazone, which reflects its trough concentration, was 452% (P = 5·10-5, 90%
CI 317–645%), when compared to control. Furthermore, clopidogrel prolonged the t½ of pioglitazone
from 6.7 to 11 hours (P = 0.002; 90% geometric mean ratio CI 135–204%). In addition, the t½ of M-IV
and M-III were prolonged from 21 to 38 hours (P = 0.007, 90% geometric mean ratio CI 130–232%) and
from 22 to 40 hours (P = 0.006, 90% geometric mean ratio CI 136–248%) by clopidogrel, respectively.
Moreover, the tmax of pioglitazone and both of its metabolites were significantly prolonged by
clopidogrel.
Figure 7. Effect of clopidogrel on the Cmax, AUC0-?, and t½ of pioglitazone, and its primary hydroxy (M-IV)
and secondary keto (M-III) metabolites. Bars represent geometric mean ratios to the placebo phase (%)
with 90% confidence intervals. * P < 0.05, ** P < 0.005, *** P < 0.001 compared with the placebo phase.
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The three individuals carrying the CYP2C8*1/*3 genotype had the highest M-IV:pioglitazone AUC0-?
ratios in the placebo phase (P = 0.0007). They also demonstrated greater decreases in the M-
IV:pioglitazone AUC0-? ratio by clopidogrel, than did the noncarriers of CYP2C8*3 (P = 0.02), and no
significant differences in this ratio existed in the clopidogrel phase between the genotypes (P = 0.7).
There were no significant correlations between the AUC0–13h of clopidogrel, or its metabolites, and the
fold-increase in pioglitazone AUC0-?. Furthermore, the static prediction model of Study II suggested that
for substrates with an fmCYP2C8 of 60–80%, lower than 1 μM static concentrations of clopidogrel acyl-?-
D-glucuronide could cause a 210% increase in their AUC0-?, similar to the effect of clopidogrel on
pioglitazone exposure in this Study. Assuming a 10% unbound fraction, the median Cmax,u and median
Cavg,u (0–13 hours) of clopidogrel acyl-?-D-glucuronide after clopidogrel 300 mg were 0.85 and 0.26 μM,
respectively.
3. Effect of clopidogrel and prasugrel on montelukast pharmacokinetics (Study III)
Clopidogrel increased the AUC0-? of montelukast to 198% (P = 1·10-5, 90% CI 172–228%) and its primary
1,2 diol metabolite (M6) to 160% (P = 6·10-5, 90% CI 140–183%) (Figures 8 and 9), when compared with
those in the placebo phase. Moreover, clopidogrel decreased the M6:montelukast AUC0-7h ratio to 45%
(P = 6·10-7, 90% CI 40–50%) of that in the placebo phase. In addition, clopidogrel prolonged the t½ of
montelukast from 4.5 to 8.2 hours (P = 6·10-8, 90% geometric mean ratio CI 170–195%), and that of M6
from 5.0 to 9.9 hours (P = 2·10-7, 90% geometric mean ratio CI 183–218%). Clopidogrel lacked an impact
on the pharmacokinetics of the 21(S)-hydroxyl metabolite of montelukast (M5a) but caused increases
in the t½ and AUC0-? of montelukast-acyl-?-D-glucuronide (M1) that were secondary to the slowed
elimination and augmented exposure of the parent montelukast. Prasugrel caused a minor prolongation
from 4.5 to 5.2 hours (P = 0.03; geometric mean ratio 90% CI 104–127%) in montelukast t½, whereas
other pharmacokinetic variables of montelukast and its metabolites were unaffected by it.
The interaction with the clopidogrel PBPK model applying higher unbound hepatocyte-to-plasma ratio
and OATP1B1 Ki of clopidogrel acyl-?-D-glucuronide could be adequately predicted when the fmCYP2C8 of
montelukast was 0.55–0.70 with both montelukast models. However, while the clopidogrel model,
which used lower values for the aforementioned parameters, performed equally well with the
perfusion-limited montelukast liver model, it overpredicted the interaction with the permeability-
limited montelukast liver model with OATP1B1 transport model using the same fmCYP2C8 values.
Simulations of the effects of long-term dosing of 75 mg clopidogrel once daily on the plasma
concentrations of montelukast predicted on average a 1.5–2-fold increase in montelukast dose interval
AUC during steady-state conditions.
The CYP2C8 genotype did not significantly affect montelukast pharmacokinetics or the increase in the
AUC of montelukast by clopidogrel. In all three study phases, there was a trend for higher montelukast
AUC0-? in the three UGT1A3*2 noncarriers than in the nine subjects carrying the UGT1A3*2 allele, and
the largest montelukast exposures were observed in two UGT1A3*2 noncarriers during the clopidogrel
phase. The CYP2C19 genotype did not significantly affect the AUC0-13h values of clopidogrel cis-5-thiol,
carboxylic acid, or acyl-?-D-glucuronide.
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Figure 8. Effect of clopidogrel and prasugrel on the Cmax, AUC0-?, and t½ of montelukast. Bars represent
geometric mean ratios to the placebo phase (%) with 90% confidence intervals. * P < 0.05, *** P < 0.001
compared with the placebo phase.
Figure 9. Effect of clopidogrel and prasugrel on the Cmax, AUC0-?, and t½ of montelukast 1,2 diol (M6).
Bars represent geometric mean ratios to the placebo phase (%) with 90% confidence intervals. *** P <
0.001 compared with the placebo phase.
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4. Effect of clopidogrel, ritonavir, and their combination on dasabuvir pharmacokinetics, and the impact
of ritonavir on the pharmacokinetics and antiplatelet effect of clopidogrel (Study IV)
In the clopidogrel phase, the AUC0-? of dasabuvir was 467% (P = 8·10-7, 90% CI 323%–674%) of that
during placebo phase, whereas the AUC0-? of its tert?butyl hydroxyl metabolite (M1) remained
unchanged (Figure 10). Accordingly, clopidogrel decreased the M1:dasabuvir AUC0-? ratio to 17% (P =
2·10-14, 90% CI 16–19%) of that when placebo was coadministered. Moreover, clopidogrel prolonged
dasabuvir t½ from 8.4 to 15.4 hours (P = 1·10-6, geometric mean ratio 90% CI 159–213%). The 1.6-fold
increase in dasabuvir Cmax by clopidogrel did not reach the level of significance (P = 0.07, 90% CI 1.03–
2.57-fold). Furthermore, clopidogrel diminished M1 Cmax to 20% (P = 6·10-5, 90% CI 11–36%) and
prolonged the t½ of M1 from 7.9 to 17.3 hours (P = 1·10-5, geometric mean ratio 90% CI 172–281%) of
those in the placebo phase.
Figure 10. Effect of clopidogrel on the Cmax, AUC0-?, and t½ of dasabuvir and M1. Bars represent
geometric mean ratios to the placebo phase (%) with 90% confidence intervals. *** P < 0.001 compared
with the placebo phase.
Compared with ritonavir only, the combination of ritonavir and clopidogrel increased dasabuvir Cmax and
AUC0-? to 182% (P = 0.004, 90% CI 127%–261%) and 389% (P = 2·10-6, 90% CI 275%–551%), respectively
(Figure 11). Furthermore, the combination did not significantly affect the AUC0-? of M1 and thereby
decreased the M1:dasabuvir AUC0-? ratio to 20% (P = 5·10-10, 90% CI 17%–25%) of that during the
ritonavir phase. In addition, the concurrent administration of ritonavir and clopidogrel prolonged the t½
of dasabuvir and M1 from 8.2 to 11.5 hours (P = 0.005, geometric mean ratio 90% CI 114–173%) and
from 7.3 to 14.1 hours (P = 1·10-5, geometric mean ratio 90% CI 157–234%) of those in the ritonavir
phase, respectively. When compared with placebo, ritonavir did not demonstrate significant alterations
in the pharmacokinetics of dasabuvir or M1. Neither with nor without ritonavir, significant correlations
did not exist between the AUC0-? of clopidogrel acyl-?-D-glucuronide and the fold-changes in dasabuvir
AUC0-? or M1:dasabuvir AUC0-? ratio.
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Figure 11. Effect of clopidogrel-ritonavir combination on the Cmax, AUC0-?, and t½ of dasabuvir and M1.
Bars represent geometric mean ratios to the placebo phase (%) with 90% confidence intervals. *** P <
0.001 compared with the ritonavir phase.
Figure 12. The mean percent inhibition of platelet aggregation (A) and plasma concentrations of
clopidogrel active cis-5-thiol metabolite (B) after clopidogrel 300 mg. Data are presented as geometric
means (except for the mean percent inhibition of platelet aggregation, which are given as arithmetic
means) with 90% CI.
Ritonavir decreased the Cmax and AUC0-4h of clopidogrel active metabolite to 52% (P = 0.0003, 90% CI
41–65%) and 49% (P = 0.0001, 90% CI 39–61%) of those during placebo phase, respectively (Figure 12A).
In addition, the average and maximal platelet inhibition decreased from 51% and 60% in the clopidogrel
phase to 31% (P = 0.0007, SD -27 to -12); and 40% (P = 0.002, SD -29 to -11), respectively, by combining
ritonavir to clopidogrel treatment.
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5. Effect of clopidogrel and gemfibrozil on desloratadine pharmacokinetics (Study V)
In Study V, clopidogrel augmented the AUC0-? and Cmax of parent desloratadine to 280% (P = 3?10-7, 90%
CI 232–338%) and 165% (P = 0.0006; 90% CI 133–204%) of those during placebo phase, respectively
(Figure 13). The corresponding increases by gemfibrozil were to 462% (P = 4?10-7; 90% CI 346–616%)
and 174% (P = 0.0006; 90% CI 137–221%), respectively. Furthermore, the 3-
hydroxydesloratadine:desloratadine AUC0-71h ratios were 21% (P = 7?10-10, 90% CI 18–24%) and 1.7% (P
= 8?10-11, 90% CI 1.3–2.4%) of placebo during the clopidogrel and gemfibrozil phases, respectively
(Figure 14). The t½ of desloratadine was prolonged from 17 hours to 26 hours (P = 0.0003, geometric
mean ratio 90% CI 130–180%) and to 39 hours (P = 3·10-8, geometric mean ratio 90% CI 200–250%) by
clopidogrel and gemfibrozil, respectively. In addition, gemfibrozil delayed the 3-hydroxydesloratadine
tmax from 4.0 hours in the placebo phase to 11.0 hours (P = 0.009). Clopidogrel and gemfibrozil decreased
the 3-hydroxydesloratadine-O-glucuronide Cmax to 37% (P = 3·10-7, 90% CI 31–45%) and to 4% (P = 3·10-
8, 90% CI 2–6%), and diminished its AUC0-71h to 55% (P = 2·10-5, 90% CI 46–65%) and 6% (P = 7·10-8, 90%
CI 4–10%) of those in the placebo phase, respectively. In addition, the tmax of 3-hydroxydesloratadine-
O-glucuronide was delayed from 9.0 to 11.0 hours (P = 0.03). In the gemfibrozil phase, the plasma
concentrations of 3-hydroxydesloratadine and 3-hydroxydesloratadine-O-glucuronide were too low for
reliable determination of their t½ and AUC0-?.
Figure 13. Effect of clopidogrel and gemfibrozil on the Cmax, AUC0-?, and t½ of desloratadine. Bars
represent geometric mean ratios to the placebo phase (%) with 90% confidence intervals. *** P < 0.001
compared with placebo the phase.
Compared to clopidogrel phase, the AUC0-? of desloratadine was 165% (P = 2·10-5, 90% CI 142–191%)
in the gemfibrozil phase. Furthermore, in the gemfibrozil phase, 3-hydroxydesloratadine AUC0–71h was
12% (P = 1·10-8, 90% CI 9–16%) and the 3-hydroxydesloratadine:desloratadine AUC0–71h ratio was 8% (P
= 7·10-10, 90% CI 7–11%), when compared with those in the clopidogrel phase. Moreover, in the
gemfibrozil phase, the AUC0–71h of 3-hydroxydesloratadine-O-glucuronide was 11% (P = 1·10-8, 90% CI
9–15%) of that in the clopidogrel phase. A significant (Pearson two-tailed P = 0.002, R2 = 0.80) correlation
existed between the fold-change in the AUC0-? of desloratadine caused by clopidogrel and that by
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gemfibrozil. There were no significant correlations between the plasma concentrations of clopidogrel
acyl-?-D-glucuronide or gemfibrozil 1-O-glucuronide, and alterations in desloratadine
pharmacokinetics. Furthermore, regarding the pharmacokinetics of desloratadine or its metabolites,
none of the subjects was an outlier that could have been considered to exhibit desloratadine “poor
metabolizer” phenotype.
Figure 14. Effect of clopidogrel and gemfibrozil on the Cmax, AUC0-71h, and 3-
hydroxydesloratadine:desloratadine AUC0-71h that depicts the CYP2C8 activity. Bars represent geometric
mean ratios to the placebo phase (%) with 90% confidence intervals. *** P < 0.001 compared with the
placebo phase.
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DISCUSSION
1. Methodological considerations
This work sought to provide data that is applicable in clinical DDI studies and patient care, and therefore,
the studies were exclusively conducted in vivo in humans. The five pharmacokinetic studies included in
this work were randomized, prospective, and placebo-controlled in nature. As subjects’ or researchers’
expectations have no meaningful effect on pharmacokinetics, blinding was not considered necessary,
especially when the safety of the subjects was improved with this practice. Furthermore, carry-over
effects due to other reasons were also considered mechanistically unconvincing. Every study used a
crossover design, where the subjects acted as their own controls, which decreased variance in the
pharmacokinetic parameters. To ensure the elimination of the investigated drugs and the recovery of
enzyme activity after inhibitor exposure, study phases were separated by a wash-out period of two to
three weeks. The confounding factors were kept to a minimum by recruiting young adults who were
healthy, nonsmoking, and unmedicated. Depending on the drug, comorbid patients from relevant
populations might demonstrate pharmacokinetics that differ from those of healthy individuals. These
differences are modest for the drugs investigated, however, and thus the results can be applied in real-
world circumstances. To ensure compliance, the majority of the pretreatments and all the victim drugs
were administered under supervised conditions, and the perpetrator concentrations were determined
from plasma samples. Furthermore, when the researchers did not administer ritonavir or gemfibrozil in
Studies IV or V, respectively, the subjects documented the exact time of ingestion for these
pretreatments.
The dosing regimens of the examined drugs were selected to match clinical settings. In situations where
rapid P2Y12 antagonism and antiplatelet effect are required, clopidogrel is routinely commenced with a
300 mg (or even 600 mg) loading dose, and the treatment is most often continued with a 75 mg
maintenance dose (FDA 2010), and this dosing protocol was also applied in the studies. Although the
dose of clopidogrel affects its potential to alter the metabolism of victim drugs, the difference between
the effect of the loading and maintenance dose is not drastic. For example, the 300 mg dose increased
repaglinide AUC 5.1-fold, whereas the 75 mg dose augmented it 3.9-fold (Tornio et al. 2014). As
concentration-dependent adverse effects can occur rapidly after initiating a perpetrator drug to a
patient already using a victim a drug, the dosing protocol of clopidogrel applied in the studies was
appropriate. Accordingly, prasugrel, ritonavir, and gemfibrozil, as well as all the victim drugs, were
administered in clinically used doses.
To control the effect of food on pharmacokinetics, the subjects were administered standard meals after
an overnight fast during the study days. During the studies, use of other medications, nutritional
supplements, and grapefruit products was prohibited to avoid pharmacodynamic and pharmacokinetic
interactions. The sampling schedules of each study were designed to match the pharmacokinetic profile
of the drugs under investigation. Whenever the terminal t½ of the drugs or their metabolites could be
reliably determined, the AUC was extrapolated to infinity in order to reflect potential changes in dose
interval AUC in steady-state conditions. In Study I, the part of the AUC extrapolated to infinity exceeded
20% in certain study phases, and therefore, AUC0-12h was the main reported variable to reflect drug
exposure. However, when the exposure of the drugs and their metabolites were reported in the other
studies, the percentage of AUC extrapolated to infinity was lower than 20% or even 5%. The statistical
parameters and methods were applied in the studies by following the general guidelines recommended
for pharmacokinetic research (Clinical Pharmacology and Therapeutics Editorial Team 2010, FDA
2017a).
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2. Interpretations of the study results
2.1. Implications for pharmacokinetic and drug-drug interaction studies
2.1.1. Study I
Preceding Study I, an epidemiological paper associated clopidogrel use with increased risk of
myotoxicity from cerivastatin, which is a CYP2C8 and OATP1B1 substrate (Floyd et al. 2012). Clopidogrel
was also observed to increase the exposure of BCRP/OATP1B1 and CYP2C8/CYP3A4/OATP1B1
substrates rosuvastatin and repaglinide, respectively (Table 10) (Pinheiro et al. 2012, Remsberg et al.
2013, Tornio et al. 2014). Furthermore, in vitro studies and PBPK simulations suggested that in addition
to inhibiting CYP2C8, clopidogrel could also inhibit OATP1B1 and CYP3A4 (Floyd et al. 2012, Tamraz et
al. 2013, Tornio et al. 2014). Accordingly, Study I was performed in order to clarify the DDI mechanisms
of clopidogrel, especially regarding its potential to inhibit OATP1B1 and CYP3A4, which play crucial roles
in simvastatin pharmacokinetics (Backman et al. 2000, Neuvonen et al. 1998, Niemi et al. 2011,
Prueksaritanont et al. 1997, Prueksaritanont et al. 2003).
In Study I, neither the 300 mg loading dose, nor the 75 mg maintenance dose of clopidogrel affected
simvastatin pharmacokinetics to a meaningful extent. The modest increases in the AUC0-2h of simvastatin
and simvastatin acid caused by the higher clopidogrel dose were the only conspicuous alterations
observed. In vitro experiments have reported that the parent clopidogrel is a weak time-dependent
inhibitor of CYP3A4 (Tornio et al. 2014), and the unsubstantially augmented AUC0-2h by the higher
clopidogrel dose could be caused by weak inhibition of intestinal CYP3A4. However, since potent
CYP3A4 inhibitors can raise simvastatin exposure up to 20-fold (Neuvonen et al. 1998, Neuvonen et al.
2006), clopidogrel is not suspected to markedly influence the pharmacokinetics of other CYP3A4
substrates, either. Furthermore, the results from Study I indicate that OATP1B1 inhibition is very unlikely
to have a meaningful role in the DDIs caused by clopidogrel. This notion is corroborated by a clinical
report published after Studies I and II, which observed no changes in the OATP1B1 substrate pitavastatin
exposure by clopidogrel (Kim et al. 2016). These findings lead to the conclusion that CYP2C8 inhibition
by clopidogrel acyl-?-D-glucuronide is the principal mechanism in the clopidogrel-cerivastatin and
clopidogrel-repaglinide DDIs. In addition, the previously observed clopidogrel-rosuvastatin DDI is
implausibly due to OATP1B1 inhibition. Because BCRP and NTCP also contribute to the disposition of
rosuvastatin (Ho et al. 2006, Huang et al. 2006, Kitamura et al. 2008), their altered activity could
hypothetically explain the augmented rosuvastatin exposure by clopidogrel.
2.1.2. Study II
After Study I had concluded that CYP2C8 inhibition is the predominant DDI mechanism of clopidogrel,
its effect on pharmacokinetics of specific CYP2C8 substrates required exploration. Pioglitazone
metabolism is mediated mainly by CYP2C8, whereas CYP3A or other individual enzymes have only a
minor role in it. Therefore, Study II continued investigating clopidogrel’s CYP2C8 inhibitory effect with
pioglitazone as a victim drug.
Clopidogrel increased the mean pioglitazone exposure 2.1-fold while the AUC0-? of its primary M-IV and
secondary M-III metabolites remained unaffected. Accordingly, the M-IV:pioglitazone AUC0-? ratio,
which reflects the CYP2C8-mediated metabolism of pioglitazone, was decreased to 49%, when
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compared with placebo. The concentration of pioglitazone at 24 hours after its ingestion, which
corresponds to its trough concentration, was 450% of that in the placebo phase. The carriers of the
CYP2C8*3 allele exhibited the highest fold-increases in pioglitazone exposure, but the statistical power
of Study II was insufficient to draw firm conclusions about genotype effects.
A small-dose study recently corroborated the results from Study II by observing a 2.0-fold increase in
pioglitazone exposure by clopidogrel 300 mg (Kim et al. 2016). In three previous studies, gemfibrozil
increased mean pioglitazone exposure 3.2–4.3-fold (Table 10) (Aquilante et al. 2013, Deng et al. 2005,
Jaakkola et al. 2005). Furthermore, one of the studies observed a mean 5.2-fold increase in pioglitazone
AUC in 15 subjects carrying the CYP2C8*3 allele, compared with a mean 3.3-fold increase in 15
CYP2C8*1 homozygotes (Aquilante et al. 2013). When the observations from the clinical studies with
pioglitazone and clopidogrel or gemfibrozil are combined, they suggest an average fmCYP2C8 of
approximately 60–80% for pioglitazone, which is consistent with the estimation by the in vivo-in vitro
prediction model of Study II. Somewhat surprisingly, inhibiting CYP3A4, the secondary enzyme in
pioglitazone metabolism, does not lead to markedly increased pioglitazone exposure, even if CYP2C8 is
already almost completely inactivated by gemfibrozil (Jaakkola et al. 2005). As the vast majority of
ingested pioglitazone is metabolized and no other enzymes are recognized to be clinically important in
its metabolism (Eckland and Danhof 2000, Jaakkola et al. 2006a), inhibition of CYP2C8 has a smaller
effect on pioglitazone exposure than could be expected. Despite these ambiguities in the
pharmacokinetics of pioglitazone, its relatively benign adverse-effect profile and CYP2C8-selectivity
make it a potential index substrate. Pioglitazone’s mediocre sensitivity to alterations in CYP2C8 activity
limits its usefulness for the purpose, however, especially in DDIs where the perpetrator is a weak to
moderate inhibitor or inducer of CYP2C8 (Table 9).
2.1.3. Study III
Previous DDI studies have suggested montelukast as a sensitive CYP2C8 substrate owing to the marked
increase in its exposure by gemfibrozil. Due to the complexities of montelukast pharmacokinetics and
DDI mechanisms of gemfibrozil, further studies were required. Accordingly, Study III was conducted to
clarify the role of CYP2C8 in montelukast pharmacokinetics, and to compare the CYP2C8 inhibition
potential of clopidogrel to that of prasugrel.
In Study III, clopidogrel increased the exposure of montelukast 2.0-fold, and reduced the
M6:montelukast AUC0-7h ratio, which reflects the CYP2C8-mediated metabolism of montelukast, to 45%
of those in the placebo phase. Based on previous clinical data and the PBPK simulations of Study III,
OATP1B1 inhibition is unlikely to contribute to the observed effect of clopidogrel on montelukast
pharmacokinetics. Prasugrel lacked any clinically important effects on montelukast pharmacokinetics,
which makes it an unlikely perpetrator to cause marked changes in CYP2C8 activity. The minor (from 4.5
to 5.2 hours) prolongation of montelukast t½ caused by prasugrel might be a random finding, considering
that the difference barely reached the level of significance while other pharmacokinetic variables of
montelukast remained unaffected.
In Study III, the observed 2.0-fold increase in montelukast AUC by clopidogrel is smaller than could be
predicted based on previous DDI studies, where gemfibrozil has increased montelukast exposure 4.3–
4.5-fold (Table 10) (Karonen et al. 2010, Karonen et al. 2012). CYP2C8 inhibition has been mainly
accounted for the effect of gemfibrozil on montelukast disposition, but a PBPK modeling study also
suggested a role for the OATP1B1-inhibitory property of gemfibrozil (Varma et al. 2017). As clopidogrel
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inhibits CYP2C8 but not OATP1B1 in vivo in humans, the results from Study III imply that the fmCYP2C8 of
montelukast averages approximately 0.55–0.70, which is smaller than previously thought. Therefore,
one or several mechanisms, such as membrane transporter inhibition, plausibly complement CYP2C8
inhibition in the gemfibrozil-montelukast DDI. As gemfibrozil has decreased repaglinide glucuronidation
via UGT1A1 and UGT1A3 inhibition in vitro (Gan et al. 2010), and as a GWAS has implied that UGT1A3
significantly participates in montelukast metabolism (Hirvensalo et al. 2018), UGT1A3 inhibition by
gemfibrozil could theoretically complement its DDI with montelukast. In any case, montelukast’s modest
specificity and sensitivity to alterations in CYP2C8 activity make it a sub-optimal CYP2C8 probe substrate.
2.1.4. Study IV
In 2015, dasabuvir received marketing approval as a part of ritonavir-containing four-drug regimen
indicated for the treatment of HCV genotype 1 infection. The pre-marketing clinical studies found that
in the presence of ritonavir, gemfibrozil increases the AUC and t½ of dasabuvir approximately 11- and
18-fold, respectively (King et al. 2017, Menon et al. 2015). Without concurrently administered ritonavir,
however, the effect of gemfibrozil on dasabuvir metabolism was not investigated, nor was the fmCYP2C8
of dasabuvir. Furthermore, CYP3A4 was considered to participate significantly in the metabolism of
dasabuvir without concomitantly administered ritonavir. Moreover, the potential of ritonavir to modify
the pharmacokinetics and antiplatelet action of clopidogrel was also uninvestigated. Accordingly, Study
IV was conducted to examine the effect of clopidogrel on dasabuvir pharmacokinetics with and without
ritonavir, and to elucidate the impact of ritonavir on clopidogrel metabolism and antiplatelet efficacy.
In the clopidogrel phase, the exposure of dasabuvir and the M1:dasabuvir AUC ratio, which reflects the
CYP2C8-mediated metabolism of dasabuvir, were 470% and 17% of those in the placebo phase,
respectively. Compared with the ritonavir phase, the corresponding changes produced by the
clopidogrel-ritonavir combination were 390% and 20%, respectively. When compared to the placebo
phase, an insignificant trend of decreased dasabuvir concentrations was observed in the ritonavir phase.
Furthermore, in the clopidogrel-ritonavir phase, the Cmax and AUC0-4h of clopidogrel active metabolite
were 52% and 49% of those in the clopidogrel phase, respectively. In addition, ritonavir markedly
diminished the antiplatelet effect of clopidogrel.
The previous DDI studies with gemfibrozil and dasabuvir combined with the results from Study IV
indicate that dasabuvir is among the most sensitive known CYP2C8 substrates with an fmCYP2C8 of > 90%
(Table 10). According to previous data, dasabuvir 500 mg (twice the dose applied in Study IV) failed to
cause significant QTc prolongation (EMA 2014), and its Cmax was comparable to that by concurrently
administered gemfibrozil with dasabuvir 250 mg (Menon et al. 2015). While supratherapeutic dasabuvir
exposure is still suggested to possess potential to prolong the QTc interval (FDA 2014b), these
implications are not based on publicly available data. Accordingly, dasabuvir could be applied as a
CYP2C8 index substrate in clinical DDI studies, if the dosage is appropriately adjusted to ensure the
safety of studied subjects, for example, regarding the risk of cardiac adverse events (Table 9). Based on
current knowledge, it is challenging to give an exact estimate for the aforementioned dosage reduction
of dasabuvir for the purposes of DDI studies, because its fmCYP2C8 in subtherapeutic doses should first be
determined. However, examining the impact of strong CYP2C8 inhibitors on dasabuvir 50 mg (20% of
the clinical dose) could be a reasonable starting point.
The role of CYP3A4 in dasabuvir metabolism seems to be of minor importance, because if CYP3A4 would
significantly contribute to dasabuvir pharmacokinetics, coadministering ritonavir would accentuate the
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effect of CYP2C8 inhibitors on dasabuvir metabolism. As this was not the case in Study IV where ritonavir
slightly reduced the impact of clopidogrel-mediated CYP2C8 inhibition on dasabuvir pharmacokinetics,
CYP3A4 seems to metabolize dasabuvir only to a negligible extent, even without coadministered
ritonavir. The decreasing effect of ritonavir on dasabuvir concentrations lacks an unequivocal
mechanistic explanation. A PBPK modeling study explained the increase in dasabuvir clearance observed
with concurrent administration of ritonavir by hypothetical CYP2C8 induction (Shebley et al. 2017a), but
this claim is unsupported by available clinical data. Moreover, the theoretical CYP2C8 induction by
ritonavir should make the pharmacokinetics of dasabuvir more susceptible to the effects of CYP2C8
inhibitors, which was not observed in Study IV. Alternatively, induction of P-gp by ritonavir has been
suggested to account for the decrease in dasabuvir exposure (Varma et al. 2019), but the concurrent
administration of ritonavir and dasabuvir in 3D regimen would likely result in inhibition, not induction,
of P-gp. The approximately 5-fold increase in dasabuvir exposure by clopidogrel support classifying the
latter as strong CYP2C8 inhibitor (FDA 2017a). Furthermore, the exposure of clopidogrel active
metabolite and its thrombocyte aggregation inhibition were significantly reduced by ritonavir, which
corroborates the importance of CYP3A4 in clopidogrel bioactivation.
2.1.5. Study V
In 2015, an in vitro study proposed an obligatory role for CYP2C8 in the formation of the 3-hydroxy
metabolite of desloratadine (Kazmi et al. 2015), which possesses a good safety profile and could
therefore act as a CYP2C8 index substrate. Furthermore, the CYP2C8 inhibition potency of clopidogrel
had not been compared to that of gemfibrozil. Therefore, Study V was performed in order to examine
the role of CYP2C8 in desloratadine metabolism in vivo in humans, and to compare head-to-head the
magnitude of CYP2C8 inhibition produced by clopidogrel and gemfibrozil.
Clopidogrel increased desloratadine exposure to 280% and decreased the 3-
hydroxydesloratadine:desloratadine AUC0-71h ratio to 21%, when compared with those in the placebo
phase. Gemfibrozil altered the same parameters to 460% and 2% of those in the placebo phase,
respectively. Furthermore, in the gemfibrozil phase, desloratadine exposure and the 3-
hydroxydesloratadine:desloratadine AUC0-71h ratio were 160% and 8% of those in the clopidogrel phase,
respectively (Table 10). Consistently with Studies II–IV and previous reports on gemfibrozil-mediated
DDIs (Backman et al. 2016), these findings indicate that clinical doses of clopidogrel cause about 80%
inhibition of CYP2C8 activity, while those of gemfibrozil almost completely inactivate the enzyme.
The biotransformation of desloratadine to its 3-hydroxy metabolite involves three steps, as suggested
by Kazmi and colleagues: First, UGT2B10 glucuronidizes desloratadine forming an N-glucuronide
metabolite, which is then rapidly 3-hydroxylated by CYP2C8, and finally the glucuronide moiety is
deconjugated during, or right after, the CYP2C8-mediated 3-hydroxylation (Figure 4) (Kazmi et al. 2015).
The proposed metabolism route seems convincing, since desloratadine was not 3-hydroxylated by
CYP2C8 unless coincubated with UGT2B10 in vitro. The results from Study V corroborate the crucial role
of CYP2C8 in 3-hydroxydesloratadine formation, as the exposure of this metabolite was significantly
decreased by clopidogrel and almost abolished by gemfibrozil, and gemfibrozil or clopidogrel are not
known to inhibit UGT2B10. As the formation of 3-hydroxydesloratadine is also dependent on UGT2B10
activity, subjects with low UGT2B10 function may be relatively insensitive to changes in desloratadine
pharmacokinetics by CYP2C8 inhibitors. Low UGT2B10 activity could mechanistically, and consistently,
explain the desloratadine “poor metabolizer” phenotype, which has a prevalence range from 2% in
Caucasians and Hispanics to 17% in African Americans (Prenner et al. 2006). As genotypes that result in
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lowered UGT2B10 activity and the desloratadine “poor metabolizer” phenotype are observed in similar
frequencies in corresponding ethnic populations (Berg et al. 2010, Chen et al. 2010, Prenner et al. 2006),
this unconfirmed hypothesis seems plausible. For these reasons, the applicability of desloratadine as a
CYP2C8 index substrate may be compromised in populations with high prevalence of UGT2B10 loss-of-
function alleles. Furthermore, if a hypothetical perpetrator drug would inhibit UGT2B10 instead of
CYP2C8, using desloratadine as a CYP2C8 probe substrate could lead to false conclusions on the DDI
profile of the perpetrator. On the other hand, the benign safety profile and lack of CYP or transporter
inhibition could support its use for the purpose (Table 9).
In the DDIs observed in Study V, both the perpetrator and victim compounds are glucuronide
metabolites. Therefore, these results highlight the importance of screening glucuronides as potential
interacting molecules in DDI studies, especially when CYP2C8-mediated DDIs are examined. According
to the findings from Study V and previous research, gemfibrozil is a more potent CYP2C8 inhibitor than
clopidogrel in clinically relevant doses. However, clopidogrel could be applied as an optional CYP2C8
index inhibitor in situations where examining the CYP2C8-mediated metabolism of a dual
CYP2C8/OATP1B1 substrate is of special interest, in which gemfibrozil is a suboptimal CYP2C8 index
inhibitor. It should be noted that if clopidogrel is employed as a CYP2C8 index inhibitor, its CYP2B6-
inhibitory properties should be taken into account when the DDI data is being interpreted.
Table 9. Benefits, disadvantages, and clinically most important risks related to supratherapeutic
exposure of potential CYP2C8 index substrates.
Benefits as a CYP2C8
index substrate
Disadvantages as a CYP2C8
index substrate
Most important risks of
DDIs with CYP2C8
inhibitors in clinical
practise
Dasabuvir High fmCYP2C8 and
sensitivity to CYP2C8
inhibition
Adverse event characteristics
that requires subtherapeutic
dosage
Decreased hemoglobin
levels; potential for QTc
prolongation
Desloratadine High sensitivity to
CYP2C8 inhibition in
most populations;
benign adverse effect
profile
UGT2B10-mediated
glucuronidation preceding
oxidation by CYP2C8; may not
be suited in populations
where UGT2B10 loss-of-
function alleles are prevalent
Dry mouth, fatigue
Montelukast Good adverse effect
profile in single doses
Metabolism by UGT1A3;
intermediate fmCYP2C8
Headache;
neuropsychiatric
adverse effects
Pioglitazone Average-high fmCYP2C8;
well-tolerated in
single doses
Mediocre sensitivity to
CYP2C8 inhibition
Fluid retention that can
aggravate illnesses
Repaglinide High sensitivity to
CYP2C8 inhibition
OATP1B1- and CYP3A4-
mediated disposition; adverse
event profile that requires
subtherapeutic dosage
Hypoglycemia; GI
adverse events
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2.2. Clinical implications
This work has several implications of clinical importance. The specific findings concern the investigated
drug combinations and the safety of their use, and the general ones concern all drugs that have similar
DDI profile than the drugs examined. Studies II and IV had the most relevant findings concerning patient
safety, whereas the data from other studies are informative mainly for clinical DDI research.
In Study IV, the clopidogrel-ritonavir combination increased dasabuvir exposure approximately 4-fold
on average, while the largest increase was about 8-fold, when compared with ritonavir alone.
Furthermore, the combination raised dasabuvir Cmax about 2-fold; however, the increase could be
plausibly more pronounced in continuous administration. Phase II trials, which investigated dasabuvir
safety, implied that its supratherapeutic exposures are associated with hemoglobin decrease and
potential to prolong the QTc interval, and therefore, concurrent administration of gemfibrozil and
dasabuvir is contraindicated (FDA 2014b). In contrast, after PBPK simulations suggested a 2–3-fold
increase in dasabuvir exposure by clopidogrel (Shebley et al. 2017a), the United States Food and Drug
Administration (FDA) did not contraindicate their concomitant use (Arya et al. 2017). A PBPK analysis
criticized the findings of Study IV by arguing that there were two major limitations in the study design,
and thereby concluded that coadministration of clopidogrel and dasabuvir should not be
contraindicated (Shebley 2019). First, the 300 mg loading dose of clopidogrel was considered to
markedly affect the extent of the clopidogrel-dasabuvir DDI observed in Study IV, and second, the two-
day pretreatment was regarded to be insufficient to achieve full CYP2C8 induction by ritonavir, which
would hypothetically attenuate the effect of clopidogrel on dasabuvir pharmacokinetics. The rationale,
however, has several major inconsistencies (Itkonen et al. 2019). The CYP2C8-inductive effect of
ritonavir, which is unsupported by clinical data published in scientific journals, should make dasabuvir
more susceptible to CYP2C8 inhibition, not the opposite as observed in Study IV. In addition, according
to the referenced PBPK model by Shebley and colleagues, the increase in dasabuvir hepatic clearance
by ritonavir reaches about 80% of the steady state effect at 48 hours after commencing ritonavir (the
time when dasabuvir was administered in Study IV) (Shebley et al. 2017a). Furthermore, the difference
in CYP2C8 inhibition caused by the 300 mg clopidogrel does not radically differ from that caused by
clopidogrel 75 mg, as demonstrated by the approximately 20% difference in the increase in repaglinide
AUC (5.1-fold vs. 3.9-fold) by the two dosages (Tornio et al. 2014). Therefore, the results from the
aforementioned PBPK simulations cannot be used to refute the clinical observations from Study IV.
Study IV suggests contraindicating the clopidogrel-dasabuvir combination, or at least, recommends
caution when they are coadministered, especially if the patient possesses additional risk factors for the
adverse events of dasabuvir, such as electrolyte imbalances, polypharmacy with QTc prolonging drugs,
or disturbances in bone marrow function.
Study IV observed a significantly attenuated antiplatelet effect of clopidogrel and a halving of the Cmax
and AUC0-4h of its active metabolite caused by ritonavir. These findings imply that ritonavir can markedly
diminish the antithrombotic efficacy of clopidogrel, which is consistent with previous reports on patients
using ritonavir and other strong CYP3A4 inhibitors concurrently with clopidogrel (Farid et al. 2007,
Holmberg et al. 2014, Marsousi et al. 2018, Metzger and Momary 2014). Therefore, clopidogrel should
not be the primarily prescribed P2Y12 receptor antagonist for patients on ritonavir therapy.
The concentration-dependent adverse effects of pioglitazone include fluid retention that can lead to
worsening of congestive heart failure and even pulmonary edema (Waugh et al. 2006), and therefore,
European Medicines Agency (EMA) warns about coadministration of pioglitazone with gemfibrozil.
Accordingly, the mean 2.1-fold and 4.5-fold increases in pioglitazone exposure and trough
concentration, respectively, caused by clopidogrel also warrant caution if the drugs are used
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concomitantly. Similar to clopidogrel-dasabuvir combination, the risks of coadministering clopidogrel
with pioglitazone are higher in patients who are predisposed to adverse effects of the victim drug by
other factors.
Study I showed that concurrent use of clopidogrel is unlikely to lead to increased risk for adverse effects
of simvastatin due to pharmacokinetic reasons. Furthermore, despite the reported adverse effects of
montelukast, most notably neuropsychiatric symptoms, the 2-fold increase in its AUC by clopidogrel
observed in Study III is unlikely to substantially worsen the safety profile of montelukast. In addition,
prasugrel seems to be a safe alternative to clopidogrel concerning its CYP2C8-inhibitory DDI potential.
Moreover, the DDIs of desloratadine with clopidogrel and gemfibrozil reported in Study V are unlikely
to cause relevant adverse effects. This interpretation is further supported by the fact that 3-
hydoxydesloratadine also possesses H1 receptor antagonistic properties (Murdoch et al. 2003), which
implies that CYP2C8 inhibition implausibly compromises the clinical efficacy of desloratadine.
Table 10. A comparison of the fold-changes (R) in pharmacokinetic variables of CYP2C8 substrates (given
in single doses) caused by gemfibrozil and clopidogrel in Studies I–V and previous reports. Data are
expressed as either arithmetic or geometric mean ratios with 90% or 95% confidence intervals (CI), or
ranges.
Victim drug
and its dose
Clopidogrel 300 mg followed by 75 mg q.d.
ratio (R) to placebo (90% or 95% CI, or range)
Gemfibrozil 600 mg b.i.d. ratio (R) to
placebo (90% or 95% CI, or range)
AUC0-?R CmaxR Reference AUC0-?R CmaxR Reference
Dasabuvir
250 mg 4.7 (90% CI
3.2–6.7)
1.6 (90% CI
1.0–2.6)
Study IV 11.3 (90%
CI 9.1–14)
2.0 (90% CI
1.7–2.4)
(Menon et al.
2015)
Desloratadine
5 mg 2.8 (90% CI
2.3–3.4)
1.7 (90% CI
1.3–2.0)
Study V 4.6 (90% CI
3.5–6.2)
1.7 (90% CI
1.4–2.2)
Study V
Montelukast
 10 mg 2.0 (90% CI
1.7–2.3)
0.98 (90% CI
0.8–1.2)
Study III 4.4 (95% CI
3.8–5.0)
1.5 (95% CI
1.3–1.8)
(Karonen et
al. 2010)
4.3 (95% CI
2.9–6.3)
1.5 (95% CI
0.9–2.3)
(Karonen et
al. 2012)
Pioglitazone
 1 mg 2.0 (95% CI
1.6–2.5)a
not reported Kim et al.
(2016)
 15 mg 2.1 (90% CI
1.8–2.6)
1.0 (90% CI
0.8–1.4)
Study II 3.2 (range
2.3–6.5)
1.1 (range
0.5–2.6)
(Jaakkola et
al. 2005)
4.3 (95% CI
3.5–5.1)
1.3 (95% CI
1.0–1.6)
(Aquilante et
al. 2013)
30 mg 3.4 (range
2.3–6.2)
not
reported
(Deng et al.
2005)
Repaglinide
 0.1 mg 3.1 (95% CI
2.1–4.1)b
not reported (Kim et al.
2016)
 0.25 mg 5.1 (90% CI
3.9–6.6)
2.5 (90% CI
1.8–3.5)
(Tornio et al.
2014)
8.1 (range
5.5–15)
2.4 (range
1.7–6.1)
(Niemi et al.
2003)
3.9 (90% CI
2.9–5.3)c
2.0 (90% CI
1.3–3.1)c
(Tornio et al.
2014)
7.0 (range
2.9–14)
2.2 (range
1.4–2.9)
(Tornio et al.
2008)
7.6 (range
4.2–12)
2.7 (range
1.5–3.7)
(Backman et
al. 2009)
7.0 (90% CI
6.0–8.1)
2.0 (90% CI
1.6–2.5)
(Honkalammi
et al. 2012)
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aAUC0-24h ratio. bAUC0-8h ratio. cEffect on day 3 of treatment with clopidogrel 300 mg on day 1 followed by 75 mg
q.d. AUC0–9h, area under the plasma concentration-time curve from 0 to 9 h; AUC0–24h, area under the plasma
concentration-time curve from 0 to 24 h; AUC0–?, area under the plasma concentration-time curve from time 0 to
infinity; Cmax, peak plasma concentration.
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CONCLUSIONS
Based on the results of this work, the following conclusions have been made
1. Clinical doses of clopidogrel do not decrease OATP1B1 or CYP3A4 activity, but instead
cause strong CYP2C8 inhibition, which can lead to clinically relevant DDIs with CYP2C8
substrates.
2. Gemfibrozil is a stronger CYP2C8 inhibitor than clopidogrel. However, the latter may be
used as a CYP2C8 index inhibitor in situations where the investigated victim drug is also
a substrate of OATP1B1, which gemfibrozil, but not clopidogrel, inhibits.
3. Coadministering clopidogrel in clinical practise may lead to hazardous adverse events of
dasabuvir and  pioglitazone.
4. As the metabolism of dasabuvir is CYP2C8-mediated with high specificity and sensitivity,
it can be applied as a CYP2C8 index substrate, but its dosage should be reduced from the
therapeutic level to guarantee safety of subjects.
5. Montelukast, desloratadine, and pioglitazone are suboptimal CYP2C8 probe substrates
due to their mediocre fmCYP2C8, multiple metabolism routes, or both.
6. The concurrent use of strong CYP3A4 inhibitors and clopidogrel is not recommended,
because they impair its antiplatelet effect, as demonstrated by ritonavir-clopidogrel
interaction.
7. Prasugrel is unlikely to cause clinically relevant DDIs due to CYP2C8 inhibition.
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